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Sunday, September 18
4:00 - 6:30 p.m. Registration, Congressional Ballroom 
6:00 - 8:00 p.m. Opening Reception, Congressional Ballroom 
Monday, September 19 
6:30 - 8:00 a.m. Continental breakfast, Congressional Ballroom 
7:00 a.m. - 5:00 p.m. Registration, Congressional Ballroom 
8:00 - 8:15 a.m. Kenneth White, PhD, Utah State University, USA 
Summit Welcome and Opening Remarks 
8:15 - 9:00 a.m. Michael Roberts, PhD, University of Missouri, USA 
Keynote Lecture - The Current Status of Transgenic Farm Animal Research 
Session 1: Gene Editing Technology and Application 
Session Chair – Bruce Whitelaw, PhD, Roslin Institute, United Kingdom 
9:00 - 9:30 a.m. Dan Carlson, PhD, Recombinetics Inc, USA 
Efficient Genome Editing in Livestock 
9:30 - 10:00 a.m. Göetz Laible PhD, AgResearch, New Zealand 
Technological Advances Create New Opportunities for the Targeted Improvement 
of Livestock 
10:00 - 10:30 a.m. Bhanu Telugu, PhD, University of Maryland, USA 
Engineering Genomes of Domestic Pigs for Agricultural Applications 
10:30 - 10:45 a.m. Poster exhibit/beverage break, Senate Suites 
Session 2: Modification of Disease Resistance and Susceptibility in Large 
Animals 
Session Chair – Chris Davies, DVM, PhD, Utah State University, USA 
10:45 - 11:15 a.m. Kevin Wells, PhD, University of Missouri, USA 
Improved Resistance to Livestock Disease through Genetic Enhancement 
11:15 - 11:45 a.m. Jorge Piedrahita, PhD, North Carolina State University, USA 
Development and Characterization of Severe Combine Immune Deficient Swine 
11:45 a.m. - 12:15 p.m. Eddie Sullivan, PhD, SAb Biotherapeutics, USA 
The Use of Genetically Engineered Large Animals to Rapidly Respond to Emerging 
Infectious Disease through the Production of Therapeutic Antibodies 
12:15 - 1:15 p.m.  Networking lunch – Congressional Ballroom 
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Session 3: Transgenic Large Animal Models 
Session Chair - Carol Keefer, PhD, University of Maryland, USA 
1:15 - 1:45 p.m. Irina Polejaeva, PhD, Utah State University and Ravi Ranjan, MD, PhD, 
University of Utah, USA 
Transgenic Goat Model of Atrial Fibrillation 
1:45 - 2:15 p.m. Randy Prather, PhD, University of Missouri. USA 
Development of Animals Models and National Swine Research and Resource Center 
Selected abstract presentations 
2:15 - 2:30 p.m. Amy Desaulniers, University of Nebraska, USA 
Use of Genetically Engineered Swine to Elucidate Testicular Function in the Boar 
2:30-2:45 p.m. Seon-Ung Hwang, Chungbuk National University, Republic of Korea 
Production of Transgenic Pigs with pGFAP-CreERT2; EGFPLoxP Inducible System 
2:45 - 3:45 p.m. Poster session/refreshment break, Senate Suites 
Session 4: Regulation of Genetically Engineered Large Animal Models and Medical 
Device Development Tools 
Moderator - Mark Walton, PhD, Yorktown Technologies, LP, USA 
Presentations followed by a panel discussion. 
3:45 - 4:15 p.m. Malini Wileman 
4:15 - 4:45 p.m. Donna Lochner 
4:45 - 5:15 p.m. Panelists include: 
Malini Wileman, PhD, Center for Veterinary Medicine, FDA, USA 
Donna Lochner, Center for Devices and Radiological Health, FDA, USA 
Laura Epstein, J.D., Center for Veterinary Medicine, FDA, USA 
Jill Ascher, DVM, MPH, Division of Veterinary Services, Center for Biologics Evaluation 
and Research, FDA, USA. 
Tuesday, September 20 
6:30 – 8:00 a.m. Continental breakfast, Congressional Ballroom 
7:00 - 10:00 a.m. Registration, Congressional Ballroom 
Session 5: Current and Future Large Animal Models in Biomedical Research 
Session Chair - Zhongde Wang, PhD, Utah State University, USA 
8:00 - 8:30 a.m. David Ayares, PhD, Revivicor Inc., USA 
Genetically Engineered Pigs for Xenotransplantation 
8:30 - 9:00 a.m. Michael Cutler, DO, PhD, Intermountain Heart Institute, USA 
Translational Cardiovascular Research Utilizing Large Animal Genetic Engineering 
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9:00 - 9:30 a.m. Chris Rogers, PhD, Exemplar Genetics, USA 
TP53 and KRAS Targeted Pigs: A Platform for Models of Human Cancer 
Selected abstract presentations 
9:30 - 9:45 a.m. Timothy Sheets, University of Maryland, USA 
Investigating the Conserved Role of Neurogenin 3 (NGN3) in Endocrine Pancreatic 
Development in the Porcine Model Using CRISPR/Cas9 System 
9:45 - 10:00 a.m. Min Yang, Utah State University, USA 
Introduction of Callipyge Mutation into the Goat Genome Using Transcription  
Activator-like Effector Nucleases (TALENs). 
10:00 - 10:30 a.m. Poster session/beverage break, Senate Suites 
Session 6: Funding Mechanisms to Support Genetically Engineered Livestock 
Research 
Moderator - Kenneth White, PhD, Utah State University, USA 
Presentations followed by a panel discussion 
10:30 – 10:50 a.m. Ravi Ravindranath 
10:50 – 11:10 a.m. Adele Turzillo 
11:10 – 11:30 a.m. Miguel Contreras 
11:30 a.m. – 12:00 p.m. Panelists include: 
Ravi Ravindranath, DVM, PhD, National Institutes of Health, Reproductive Sciences 
Branch, USA 
Adele Turzillo, USDA, National Institute of Food and Agriculture, USA 
Miguel Contreras, PhD, National Institutes of Health, Office of Research Infrastructure 
Programs, USA 
Michael Roberts, PhD, Curator’s Professor of Biochemistry and Animal Sciences, 
University of Missouri, Member of the National Academy of Sciences, USA 
12:00 - 1:00 p.m. Networking lunch, Congressional Ballroom 
Session 7: Current and Future Large Animal Models in Biomedical Research 
Session Chair - Jon Oatley, PhD, Washington State University, USA 
1:00 - 1:30 p.m. Eckhard Wolf, University of Munich Gene Center, Germany 
Genetically Tailored Pig Models for Translational Diabetes Research 
1:30 - 2:00 p.m. Ann Harris, PhD, Feinberg School of Medicine, Northwestern University, 
USA 
Why Might New Large Animal Models of Cystic Fibrosis Be Useful for Generating 
New Therapies? 
2:00 - 2:30 p.m. Noelle Cockett, PhD, Executive Vice President and Provost, Utah State 
University, USA 
Future Perspectives and Closing Remarks 
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Summit Welcome and Opening Remarks 
Dr. Kenneth White, PhD, Utah State University, USA 
Ken White is dean of the College of Agriculture and Applied Sciences at Utah State 
University, the vice president for USU Extension and director of the Utah Agriculture 
Experiment Station. Dr. White will open the summit and introducing the keynote speaker. 
Dr. White is known for his partnership in creating the first successful equine clones. He is 
also interested in research of early development and reproduction.  
Keynote Lecture 
Michael Roberts, PhD, University of Missouri 
S1: The Current Status of Transgenic Farm Animal Research 
R. Michael Roberts1, 2
1Division of Animal Sciences and, University of Missouri, Columbia, MO, USA; 2Bond 
Life Sciences Center, University of Missouri, Columbia, MO, USA  
I will provide a brief and general account of transgenic research in farm animals, beginning 
with approaches that introduced genetic material directly into a pronucleus of the fertilized 
egg and concluding with gene editing by CRISPR/Cas9 technologies. Following this 
introduction, I’ll cover the fraught topic of pluripotent stem cells, including the perceived 
promise of such cells for transgenic research and the disappointing outcomes that have 
followed the initial enthusiasm. I’ll conclude this section with an account of why I believe 
such cells have continued relevance for both biomedical and agricultural purposes and 
present recent data from mine and Dr. Randall Prather’s laboratory on an improved means 
for in vitro maturation (IVM) of porcine oocytes. It is generally recognized that the 
attainment of development competency in in vitro-derived oocytes continues to be a 
challenge for assisted reproductive technologies (ART) in agriculturally important, large 
farm species, because IVM oocytes are less competent than their in vivo counterparts, 
particularly if they are derived from immature animals. I shall describe how three growth 
factors (FGF2, LIF, IGF-1), when added to an otherwise standardized IVM medium, are 
able to double the number of high-quality blastocysts that can be generated from a set 
number of oocytes derived from immature gilts. These oocytes provide close to normal size 
litters of healthy piglets following either somatic cell nuclear transfer or CRISPR/Cas9 gene 
editing in the zygote. These cytokines work synergistically in promoting oocyte IVM and 
induce hitherto unnoticed fluctuations of MAPK concentrations in cumulus cells (CCs) 
investing the oocytes, a phenomenon that appears to underpin the observed improvement in 
oocyte competence.    
Michael Roberts is a Curators’ Professor of biochemistry and animal sciences at the 
University of Missouri. He is a member of the National Academy of Sciences and 
internationally recognized for the discoveries of interferon-tau and other pregnancy-
associated proteins. He has published over 300 papers in refereed scientific journals and 
over 70 reviews and book chapters. Dr. Roberts also received the prestigious Milstein Prize 
for Research on interferons and the Wolf Prize in Agriculture. 
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Session 1 - Gene Editing Technology in Livestock and Applications 
Session Chair - Bruce Whitelaw, PhD, Roslin Institute, United Kingdom 
Bruce Whitelaw was awarded a Bachelor of Science degree in Medical Microbiology from 
the University of Edinburgh in 1982 and his PhD in 1987 from the University of Glasgow. 
Currently, Bruce is head of Division of Developmental Biology at The Roslin Institute and 
professor of Animal Biotechnology at the Royal (Dick) School of Veterinary Studies. 
Having pioneered the use of lentivirus vectors for transgene delivery, he is currently 
establishing robust methodology for genome editing in livestock. 
Dan Carlson, PhD, Recombinetics Inc. 
S2: Efficient Genome Editing in Livestock 
Daniel F. Carlson1, Adrienne L. Watson1, Dennis A. Webster1, Scott C. Fahrenkrug1 
1 Recombinetics Inc., St. Paul, Minnesota, USA 
Livestock harboring directed genetic compositions have tremendous potential for 
improvement of agricultural animals/products, regenerative medicine technologies and 
creation of large-animal models for preclinical assessment of therapeutics for safety and 
efficacy. A brief overview of editing platforms in livestock will be discussed followed by 
three examples where the technology was used to produce three “personalized” animal 
models of disease.  Dilated cardiomyopathy (DCM) is a major cause of heart failure and a 
significant source of mortality and morbidity for children and adults. To create this model, 
we have leveraged the discovery of human mutations in RNA Binding Motif 20 (RBM20), 
an RNA-splicing protein. Pigs homozygous for the human mutant allele RMB20 R636S 
have severe and rapid onset of DCM leading to prototypical heart failure with reduced 
ejection fraction and fibrotic myocardium. Heterozygous animals suffer from a more latent 
form of disease consistent with heart failure in adult patients. The NF1 pig was developed 
by engineering a premature termination codon into minipigs that mimics a common disease 
allele in patients. We have observed a striking 100% penetrance of café au lait spots in 
these pigs, a phenotype that is seen in patients, but has never been demonstrated in any 
other animal model.  Fibroblasts isolated from NF1 pigs also show hyperactive Ras activity, 
the underlying mechanism of human disease.  Progress in characterization of other typical 
clinical presentations in NF1 patients will be reported. Complimentary to gene editing, 
transposon transgenesis is also a reliable tool for delivery of humanized mutant alleles.  
Transgenic Ossabaw expressing a gain-of-function chimp PCSK9transgene have 
significantly increased cholesterol (5 to 15-fold, depending on diet) that leads to highly 
occlusive, mature atherosclerotic plaques characterized by high levels of inflammation, 
calcification and necrosis within the core of the coronary lesions. 
Dan Carlson is a “farm kid” from southwestern Minnesota who interest in biotechnology 
when his family began planting genetically modified crops in the 90s. He attended the 
University of Minnesota where he earned a PhD in animal science with an emphasis in 
biotechnology and molecular genetics. The focus of his research is the refinement and 
application of methodology for genetic engineering in livestock. Through his 13 years in 
biotechnology research, Dan has led the development of transposon systems and gene-
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editing technology in livestock. Dan is the vice president of development at Recombinetics 
where he directs the application of gene-editing to develop products while continuing to 
innovate in the field of genome engineering and develop intellectual property. 
Göetz Laible, PhD, AgResearch 
S3: Technological Advances Create New Opportunities for the Targeted 
Improvement of Livestock 
Göetz Laible1, Brigid Brophy1, David Wells1, Sally Cole1, Marion Wright1, Stephanie 
Delaney1, Ali Cullum1, Aaron Malthus1, Jingwei Wei1, Stefan Wagner1 
1 Animal Science, Reproduction, AgResearch Ruakura, Hamilton, New Zealand 
Over millennia humans have modified the genetic makeup of livestock by breeding and 
selection strategies to better meet the need for food and other animal products. Although 
this strategy has been proven to be highly successful, improvements are generally limited to 
incremental steps and typically require the accumulation of small gains over long periods to 
realize genuine benefits. The development of transgenic livestock technology now provides 
a powerful alternative where it is possible to directly introduce genetic modifications with 
known impact and potentially achieve benefits within a single generation. While initially 
the technology was held back by technical limitations, these have been largely overcome by 
progressive improvements over the past 30 years. In particular, the development of site-
specific nucleases facilitating the efficient and precise editing of livestock genomes makes 
it now possible to directly introduce and accumulate favourable alleles in the best animals. 
This next generation breeding approach was recently exemplified with the production of 
hornless dairy cattle.  
Considering the importance of milk as a human food, the rational improvement of milk 
composition of dairy animals was one of the earliest goals with the development of 
transgenic livestock capabilities. The newly available precision tools create exciting new 
options for genetically engineering milk. The presentation will provide an overview about 
the humble beginnings and what might be possible now and in the near future to improve 
milk for human consumption with these new technologies. 
Göetz Laible is a senior scientist at AgResearch, New Zealand’s largest Crown Research 
Institute. He holds a PhD in biochemistry from the Free University of Berlin, Germany and 
carried out his postdoctoral research at the Salk Institute for Biological Studies in San 
Diego. He leads a research program focused on the development and evaluation of genome 
modification technologies for future livestock applications. 
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 Bhanu Telugu, PhD, University of Maryland 
S4: Engineering Genomes of Domestic Pigs for Agricultural Applications 
 
Ki-Eun Park1,2, Chi-Hun Park1,2, Anne Powell2, David M. Donovan1,2, Bhanu P. Telugu1,2,* 
1 Department of Animal and Avian Sciences, University of Maryland, College Park, MD, 
USA; 2Animal Bioscience and Biotechnology Laboratory, USDA, ARS, Beltsville, MD, 
USA 
 
The breeding of domestic animals has a longstanding and successful history, starting with 
domestication several thousand years ago. Modern animal breeding strategies 
predominantly based on population genetics, artificial insemination (AI) and embryo 
transfer (ET) technologies have led to significant increases in the performance of domestic 
animals, and are the basis for regular supply of high quality animal derived food at 
acceptable prices. However, the current strategy of marker-assisted selection and breeding 
of animals to introduce novel traits over multiple generations is too pedestrian in 
responding to unprecedented challenges such as changing climate, global pandemics, and 
feeding an anticipated 33% increase in global population in the next three decades. Here, 
we propose site-specific genome editing technologies as a basis for “directed” or “rational 
selection” of agricultural traits. These genome editing tools are expected to facilitate 
targeted modification of individual traits without affecting the overall genetic merit of the 
animal thereby ushering the animal biotechnology into the functional genomics era. The 
animal science community envisions these technologies as essential tools in addressing 
critical priorities for global food security and environmental sustainability, and strives to 
develop these technologies for maximum societal benefit. This work is supported by 
funding from NIH-NIFA Dual Purpose with Dual Benefit Grant # 2015-67015-22845. 
 
Bhanu Telugu’s primary appointment is with the University of Maryland, where he is an 
assistant professor in the Department of Animal and Avian Sciences. He also holds a 
“visiting scientist” appointment with the USDA’s Agricultural Research Service. His 
laboratory employs genome-editing tools such as CRISPRs and TALENs for site-specific 
alterations of the pig genome for biomedical and agricultural applications. 
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Session 2: Modification of Disease Resistance and Susceptibility in Large 
Animals 
Session Chair - Chris Davies, DVM, PhD, Utah State University, USA 
Chris Davies is a research associate professor in the Department of Animal, Dairy and 
Veterinary Sciences at Utah State University, director of the university’s Center for 
Integrated BioSystems and associate director of the Utah Agricultural Experiment Station. 
His research interests include immune responses and gene expression at the maternal- fetal 
interface. Additionally he is interested in the identification and characterization of genes 
affecting immune function and disease resistance. 
Kevin Wells, PhD, University of Missouri 
S5: Improved Resistance to Livestock Disease through Genetic Enhancement 
Kevin D. Wells1 
1Division of Animal Sciences, University of Missouri, Columbia, MO, USA 
It has been more than three decades since genetic engineering (GE) technologies were first 
adapted for use in livestock.  The earliest attempts to apply GE to agricultural phenotypes 
were related to growth.  In part, this focus was due to limitations in knowledge of gene 
function and the role of genes in physiological phenomena.  However, GE efforts soon 
expanded to include disease resistance phenotypes.  In the first decade of livestock GE, 
most of the real success was related to gleaned insight into the design of transgenes.  
Examples of health-related transgenes included MX1, specific immunoglobulins, and viral 
proteins.  However, pronuclear microinjection proved to be inefficient and cost-prohibitive 
for many researchers, thus restricting the pace of GE. After the advent of animal cloning via 
somatic cell nuclear transfer, the costs of GE animal production was reduced.  Among the 
first applications of the technology was again disease resistance, specifically, mastitis 
resistance.  Recently, with the advent of designed nucleases (CRISPR technology in 
particular), not only was the cost of entry reduced, but the required skill level was also 
reduced.  As a result, more groups (commercial and academic) have the capacity to modify 
livestock genomes.  Since these new genome-editing technologies include the ability to 
make small changes that do not introduce transgenes, commercial interests have entered 
into the field with the hope of producing agricultural animals with economically viable 
phenotypes.  This hope spurs from the assumption that small genome changes will be more 
acceptable to government regulators and/or the public.  Although acceptance of GE in food 
animals remains unknown, it is clear that GE technologies have matured to the point that 
useful, viable animals can be produced.  In addition, there are examples of disease 
resistance phenotypes that cannot currently be addressed by any other technology.  The 
future of animal agriculture may depend entirely on the how regulators react to the very real 
benefits that GE livestock present.  In addition, genetic engineers need to proceed carefully 
as to not select for resistant pathogens or create new pathogen reservoirs. 
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Kevin Wells received his PhD in genetics from North Carolina State University. He now 
serves as an assistant professor at the University of Missouri with research appointment in 
the College of Agriculture, Food and Natural Resources. 
Jorge Piedrahita, PhD, North Carolina State University 
S6: Development and Characterization of Severe Combine Immune 
Deficient Swine 
Renan B. Sper & Jorge A. Piedrahita. Comparative Medicine Institute and College of 
Veterinary Medicine, North Carolina State University.   
The goal of engrafting human cells into other species, in particular hematopoietic stem 
cells, has been pursued for six decades. This goal remains and there are multiple labs across 
the world that are using, and improving humanized mice to address a range of high impact 
biomedical questions. However there is a need for developing systems in species that more 
closely resemble humans in size, physiology and longevity. The pig offers an exceptional 
and perhaps the best system for this purpose. Pigs are widely available and the life span, 
and cell and organ physiology more closely approximates those of human.  Pigs are readily 
bred, born in litters and amenable to genetic engineering.  Additionally, recent advances in 
gene editing have allowed the development of complex multi-transgenic pigs at very high 
efficiencies.  We will describe the development of a IL2RG/RAG1 deficient pig and its 
utilization for allogenic and xenogeneic engraftment.   
Jorge Piedrahita is a professor in the Department of Molecular Biomedical Sciences in the 
College of Veterinary Medicine at North Carolina State University. He is also the director 
of the Comparative Medicine Institute, a university-wide center that incorporates over 160 
faculty members from 23 different departments and five colleges. 
Eddie Sullivan, PhD, SAb Biotherapeutics 
S7: The Use of Genetically Engineered Large Animals to Rapidly Respond 
to Emerging Infectious Disease through the Production of Therapeutic 
Antibodies 
Eddie J. Sullivan1, Hua Wu1, Jerry Pommer1, Jin-An Jiao1 
1SAB Biotherapeutics, Inc., Sioux Falls, SD, USA 
SAB Biotherapeutics (SAB) has successfully developed a unique transchromosomic (Tc) 
bovine platform that can rapidly produce potent, fully human, immunoglobulins against a 
variety of disease targets including viruses and bacteria in significant quantities (up to 
600g/month/animal of highly purified immunoglobulin). Several forms of passive 
immunotherapy to prevent and treat viral infection have and are being studied in animals. 
Convalescent plasma have been used in humans, but logistical and production limitations 
have prevented widespread use. Additionally, convalescent plasma and specific monoclonal 
antibodies to viruses are unlikely to have significant cross-protection efficacy against other 
strains.  To overcome these limitations, we propose the use of a novel platform to rapidly 
produce and deliver high-titer human polyclonal immunoglobulin for treatment and post-
exposure prophylaxis of viruses and other infectious and toxin-mediated diseases. SAB has 
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developed a Tc bovine in which the bovine immunoglobulin genes have been knocked out 
and a human artificial chromosome (HAC) containing the full germ line sequence of human  
immunoglobulin has been inserted. Each Tc bovine can produce 150 to 600 grams per  
month of purified immunoglobulin and the platform is rapidly scalable. Experimental high-
titer immunoglobulins have been rapidly produced against tri-valent seasonal influenza 
(pH1N1, H3N2, type B), bi-valent hantavirus (Andes, Sin Nombre), tri-valent alphavirus 
(VEE, EEE, WEE), MERS-CoV, and anthrax, among others.   
 
Eddie Sullivan is the president and CEO of SAb Biotherapeutics, a company that produced 
the world’s first large animal species that produces fully human polyclonal antibodies. 
Eddie has been a thought leader in this field and worked with various committees and 
discussion groups that have focused on animal biotechnology and has actively participated 
in discussions for establishing a regulatory framework for this technology.  
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Session 3: Transgenic Large Animal Models 
Session Chair - Carol Keefer, PhD, University of Maryland, USA 
Carol Keefer has done pioneering work in the development of in vitro production 
techniques in cattle, including in vitro fertilization, intracytoplasmic sperm injection, and 
nuclear transfer. She is noted for work that produced the first clone goats using in vitro 
transfected donor cells. Dr. Keefer is on the editorial board of Cloning & Stem Cells and is 
a past president, vice president and member of the board of governors of the International 
Embryo Transfer Society. 
Irina Polejaeva, PhD, Utah State University 
Ravi Ranjan, MD, PhD, University of Utah 
S8: TGF-β1 Transgenic Goat Model of Atrial Fibrillation 
Irina A. Polejaeva 1, Ravi Ranjan2, Christopher J. Davies 1, Kenneth L. White 1   
1 Department of Animal, Dairy and Veterinary Sciences, Utah State University, Logan, UT, 
USA; 2  Division of Cardiology, University of Utah, Salt Lake City, UT, USA  
Large animal models of progressive atrial fibrosis provide an attractive platform to study 
the relationship between structural and electrical remodeling in atrial fibrillation (AF). Here 
we established a new transgenic goat model of AF with cardiac specific overexpression of 
TGF-β1 and investigated the changes in the cardiac structure and function leading to AF. 
Transgenic goats with cardiac specific overexpression of constitutively active TGF-β1 were 
generated by somatic cell nuclear transfer. We examined myocardial tissue, ECGs, 
echocardiographic data, and AF susceptibility in transgenic and wildtype control goats. 
Transgenic goats exhibited a significant increase in fibrosis and myocyte diameter in their 
atria compared to controls, but not in their ventricles. P-wave duration was significantly 
greater in transgenic animals starting at 12-months of age, but no significant chamber 
enlargement was detected, suggesting conduction slowing in the atria. Furthermore, this 
transgenic goat model exhibited a significant increase in AF vulnerability. Six of eight 
transgenic goats (75%) were susceptible to AF induction and exhibited sustained AF (>2 
minutes), whereas, none of six controls displayed sustained AF (P<0.01). Length of induced 
AF episodes was also significantly greater in the transgenic group compared to controls 
(687±212.02 vs. 2.50±0.88 seconds, P<0.0001).   
Marked atrial fibrosis, P-wave prolongation and a significant increase in AF susceptibility 
(following a brief electrical induction) are the primary hallmarks of this TGF-β1 transgenic 
goat model. In humans, the prevalence of AF increases with age due to atrial substrate 
remodeling developing slowly over many decades of life. These transgenic goats for the 
first time provide a large animal model where progressive accumulation of fibrosis creates 
the basis for developing AF. Serial electrophysiological studies done over time with fibrosis 
progression in this model can lead to further mechanistic understanding of AF. We suggest 
that these studies will open new clinically relevant mechanism-based targets for the 
prevention and treatment of AF.   
Irina Polejaeva is an associate professor in the Department of Animal, Dairy and 
Veterinary Sciences at Utah State University and a member of Utah Multidisciplinary 
Arrhythmia Consortium. Dr. Polejaeva is also a member of the Veterinary Diagnostics and 
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Infectious Disease USTAR program. She served for 8 years as chief scientific officer at 
ViaGen Inc., led the Cell Biology Group and was project manager for the Porcine Nuclear 
Transfer Program at PPL Therapeutics Inc. Her work led to generation of the world’s first 
cloned pigs by somatic cell nuclear transfer (SCNT) and the birth of the world’s first 1, 3-
galactosyltransferase deficient pigs. Her primary emphasis is development of GE large 
animal models for biomedical research. 
Ravi Ranjan, M.D., Ph.D., is a cardiologist specializing in cardiac electrophysiology. His 
clinical interests include ablation of complex cardiac arrhythmias like atrial fibrillation, 
ventricular tachycardias and supra-ventricular tachycardias. He also has keen interest in 
cardiac device based therapy like cardiac resynchronization therapy, ICDs and pacemakers. 
He has been a faculty member at the University of Utah since 2010. He received his 
medical degree from Harvard Medical School, completed an internal medicine residency at 
Massachusetts General Hospital, Harvard Medical School, a cardiology fellowship at Johns 
Hopkins Hospital and a cardiac electrophysiology fellowship at Johns Hopkins Hospital. 
Dr. Ranjan has built a large clinical cardiology and electrophysiology practice in Utah. 
Randy Prather, PhD, University of Missouri 
S9: Development of Animal Models and National Swine Research and 
Resource Center 
Randall S. Prather, Kevin D. Wells  
Division of Animal Sciences, National Swine Resource and Research Center, University of 
Missouri, Columbia, MO, USA  
There is an urgent need from human medicine, basic biology and production agriculture for 
genetically engineered (GE) swine. Human medicine demands models that faithfully 
replicate the human condition to develop treatments, and to practice techniques to cure 
human aliments. In some cases, swine are by nature appropriate, e.g. cardiovascular 
disease, etc. However, in other cases GE makes swine the species of choice for modeling 
humans to characterize development and progression of disease, and to develop treatments 
and therapies, e.g. cystic fibrosis, diseases of retinal degeneration, etc. A human sized 
model is necessary for developing devices, stem cell therapy strategies, and scaling 
treatments. Swine are the species of preference for providing organs for xenotransplantation 
to humans. The National Institutes of Health (NIH) has considered swine important enough 
to their mission of meeting the critical need of models that it established the National Swine 
Resource and Research Center (NSRRC). The NSRRC imports models created by others, 
curates models (as both live animals and frozen genetics), creates models as requested by 
the NIH community, and distributes cells tissues and animals to other not-for-profits.  
Applications of GE swine to areas other than medicine are equally justifiable. These range 
from understanding basic animal physiology, improving productivity, decreasing inputs, 
and changing the carcass composition, to making animals resistant to disease. GE of 
domestic pigs can help to address threats to our food security, and improve both 
sustainability and animal welfare. One recent example is that of using gene editing to make 
pigs resistant to porcine reproductive and respiratory syndrome virus (PRRSV). 
PRRSV costs $6M/day in North America and Europe. The potential economic, 
sustainability, and animal welfare benefits clearly justify GE swine for applications beyond 
resistance to PRRSV. We propose that the United States Department of Agriculture 
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establish a National Agricultural Swine Resource and Research Facility (NASRRF) that 
would focus on GE of swine. The NASRRF would respond to agricultural researchers 
across the country to provide not only models to better understand basic physiology, but 
also to make animals that would address the important issues facing the swine industry.  
Clearly, the technology is now advanced to the point where investments need to be made in 
GE of swine for both production agriculture and human medicine. 
Randy Prather is currently a Curators’ Professor with the title of Distinguished Professor 
of Reproductive Biotechnology in the Division of Animal Science at the University of 
Missouri. He is also the director of the NIH-funded National Swine Resource and Research 
Center. His lab has made over 1000 cloned pigs at MU representing over 45 different 
genetic modifications for agriculture and medicine. 
Amy Desaulniers, PhD Student, University of Nebraska 
S10: Use of Genetically Engineered Swine to Elucidate Testicular Function 
in the Boar 
Amy T. Desaulniers1, Rebecca A. Cederberg1, Clay A. Lents2 and Brett R. White1  
1Department of Animal Science; University of Nebraska-Lincoln, Lincoln, NE, USA; 
2USDA, ARS, USMARC, Clay Center, NE, USA 
The second mammalian GnRH isoform (GnRH-II) and its specific receptor (GnRHR-II) are 
highly expressed in the testis. Coding errors prevent their production in many species, but 
both genes are functional in swine. We demonstrated that GnRHR-II localizes to porcine 
Leydig cells and GnRH-II stimulates testosterone production in vivo, despite negligible 
luteinizing hormone (LH) secretion. These data indicate that GnRH-II directly effects 
testicular steroidogenesis. To explore this hypothesis, we produced a GnRHR-II 
knockdown (KD) swine line. Upon evaluation during pubertal development, testosterone 
concentrations were reduced in transgenic compared to littermate control males. However, 
LH was unaffected, suggesting that GnRHR-II KD impairs steroidogenesis directly at the 
testis rather than inhibiting gonadotropin secretion. Based on these results, our next 
objective was to compare diurnal secretory patterns of testosterone in mature transgenic (n 
= 5) and littermate control (n = 5) males. Boars were fit with indwelling jugular cannulae 
and blood was collected every 15 min for 8 h. Serum testosterone concentrations were 
quantified via radioimmunoassay. Next, males were euthanized; testis weight was recorded 
and testicular tissue collected to confirm GnRHR-II KD in transgenics via digital droplet 
PCR (normalized to β-actin). Results revealed that testosterone was unaffected by time or 
line x time interaction (P > 0.05), but a line effect was detected (P = 0.04). Differences were 
dramatic; testosterone levels were reduced by 82% in GnRHR-II KD (0.75 ± 0.05 ng/ml) 
compared to control (4.09 ± 0.29 ng/ml) males. Despite divergent testosterone 
concentrations, testis weights were similar between lines (P > 0.05), suggesting diminished 
Leydig cell function versus hypotrophy/hypoplasia. Since testicular GnRHR-II mRNA 
levels were reduced by 69% in transgenics (P < 0.001), these data demonstrate that GnRH-
II and its receptor play a critical role in testosterone biosynthesis within porcine Leydig 
cells. Given that testosterone and its metabolites dictate male reproductive success, GnRH-
II and its receptor represent unique targets to improve boar fertility. Notably, these swine 
represent the first genetically engineered animal model to examine the role of GnRH-II and 
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its receptor in mammals. Supported by NIFA Hatch (NEB-26-199; BRW) and AFRI (2011-
67015; CAL) funds. USDA is an equal opportunity provider and employer. 
Seon-Ung Hwang, Chungbuk National University, Korea 
S11: Production of Transgenic Pigs with pGFAP-CreERT2; EGFPLoxP 
Inducible System 
Seon-Ung Hwang1,2, Junchul David Yoon1,2, Kiyoung Eun3, Hyunggee Kim3,* and Sang-
Hwan Hyun1,2* 
1Laboratory of Veterinary Embryology and Biotechnology, Veterinary Medical Center and 
College of Veterinary Medicine, Chungbuk National University, 1 Chungdae-ro, Seowon-
gu, Cheongju 28644, Republic of Korea; 
2Institute of Stem Cell & Regenerative Medicine, Chungbuk National University, 1 
Chungdae-ro, Seowon-gu, Cheongju 28644, Republic of Korea; 
³Department of Biotechnology, School of Life Sciences and Biotechnology, Korea 
University, Seoul 02841, Republic of Korea.  
Transgenic (TG) pigs are currently believed to be an important model for biomedical 
research, including for disease models, pharmaceutical toxicity testing and regenerative 
medicine. In the present studies, we constructed two vector systems using pGFAP 
promoter; one retains pGFAP promoter-CreERT2 transgene and the other has enhanced 
green fluorescent protein (EGFP) gene flanked by LoxP sites which can be eliminated 
through the CreERT2-mediated recombination. We also established donor transgenic pig 
fibroblasts with pGFAP-CreERT2+LCMV-EGFPLoxP for somatic cell nuclear transfer 
(SCNT). Then, to produce TG pigs with pGFAP-CreERT2; LCMV-EGFPLoxP transgene 
constructs, embryo transfer was performed three times just before ovulation state of the 
surrogate mothers. One of them was pregnant, and delivered five TG pigs at 115 days after 
pregnancy. Polymerase chain reaction (PCR) analysis with genomic DNA prepared from 
skin tissues of TG pigs revealed that all five TG pigs had transgenes. In addition, EGFP 
expression in all organs tested was confirmed by autopsy and PCR. The real-time PCR 
analysis showed that pGFAP promoter-driven CreERT2 mRNA was highly expressed in 
the cerebrum. Three months after birth, TG pig was orally administrated with 15 mg/kg of 
4-hydroxytamoxifen (TM) during 5 days, and then euthanized after 7 days. Semi-nested
PCR analysis with genomic DNA revealed that the CreERT2–mediated recombination was
induced in the cerebrum and cerebellum, but not skin. Taken altogether, we generated TG
pig with TM-inducible pGFAP-CreERT2; EGFPLoxP recombination system by SCNT. The
current study is the first report of the astrocyte-specific pGFAP-CreERT2 inducible system
in TG pigs. Therefore, we suggest that this technology will be a useful tool for studying
physiology of astrocytes and generatingTG pig model of CNS diseases such as
Huntington’s disease, Alzheimer’s disease and brain tumor. Keywords: Porcine, SCNT,
CreERT2 system, GFAP This work was supported, in part, by a grant from the
"Cooperative Research Program for Agriculture Science & Technology Development
(Project No. PJ011288, PJ011077)" Rural Development Administration, and the "National
Research Foundation of Korea Grant funded by the Korean Government (NRF-
2013R1A2A2A04008751)", and the "Ministry of Trade, Industry & Energy(MOTIE),
Korea Institute for Advancement of Technology(KIAT) through the Leading Industry
Development for Economic Region (Project No. R0004357)", Republic of Korea.
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Session 4: Regulation of Genetically Engineered Large Animal Models and 
Medical Device Development Tools, Presentations and Panel Discussion  
 
Moderator - Mark Walton, PhD, Yorktown Technologies, LP, USA 
 
Mark Walton is a veteran of the plant and animal biotechnology industries. He has worked 
as a research scientist, entrepreneur and corporate executive. In 2016 he joined Yorktown 
Technologies, LP, the developer of GloFish Fluorescent Fish, to lead a new division, 
Ornamental Bio. Previously he was the chief marketing officer for Recombinetics.  
Dr. Walton played a key role in obtaining the Cloning Risk Assessment and the Guidance 
on Regulation of Genetically Engineered Animals from the U.S. Food and Drug 
Administration. 
 
Malini Wileman, PhD, Biologist, Center for Veterinary Medicine, FDA, USA 
 
Dr. Wileman (née Mansharamani) is a highly skilled regulatory reviewer with technical 
expertise in cell and molecular biology, biochemistry, and biotechnology. She draws on her 
9 years of combined regulatory experience in human and animal biologics development and 
manufacture as the lead scientist at the Center for Veterinary Medicine at the FDA, for 
several technical and policy-making issues, particularly emerging technologies, biopharm 
animal production, and inter-center collaboration and review. Dr. Wileman obtained her 
PhD in Biomedical Sciences from the Texas Tech University Health Sciences Center. After 
completion of her post-doctoral research at the Johns Hopkins School of Medicine in 
Baltimore, MD, Dr. Wileman worked in biologics manufacturing and process validation at 
BioReliance, and joined the FDA in 2009. 
 
Donna Lochner, Senior Scientific Advisor, Center for Devices and 
Radiological Health, FDA, USA 
 
Donna Lochner is associate director of the Office of Science and Engineering Laboratories 
at the FDA where she manages regulatory science initiatives. Prior to her current position, 
she was deputy director of the FDA’s Division of Cardiovascular Devices and chief of 
FDA’s Intraocular and Corneal Implants Branch. Before joining the FDA, Donna worked 
for Cordis Corporation. She earned a degree in chemical engineering from the Pennsylvania 
State University. 
 
Laura Epstein, Senior Analyst, Center for Veterinary Medicine, FDA, USA 
 
As a senior policy analyst for the U.S. Food and Drug Administration’s Center for 
Veterinary Medicine (CVM), Laura Epstein analyzes proposed policies and evaluates the 
effects of existing ones in order to help the FDA make informed decisions and achieve the 
center’s mission to protect human and animal health. The CVM approves animal drugs and 
monitors their safety and efficacy for companion and food-producing animals. 
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Jill Ascher, DVM, MPH, Deputy Director, Division of Veterinary Services, 
Center for Biologics Evaluation and Research, FDA, USA 
As deputy director of the Division of Veterinary Sciences at the FDA, Dr. Ascher 
participates in planning, managing, organizing and directing activities of the division to 
safeguard animal welfare by providing exceptional veterinary care throughout the animal 
program. She is committed to protecting and improving public health, and ensuring the 
safety and effectiveness of new drugs through support of regulatory sciences research.  
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Session 5: Current and Future Large Animal Models in Biomedical 
Research 
Session Chair - Zhongde Wang, PhD, Utah State University, USA 
Dr. Zhongde Wang is an associate professor in the Department of Animal, Dairy and 
Veterinary Sciences at Utah State University. In addition to his academic appointment, 
Dr. Wang is also the president, chief scientific officer and co-founder of Auratus Bio, a 
biotech company specialized in animal genetic engineering. Dr. Wang’s research team 
employs modern genome engineering tools (such as CRISPR/Cas9, TALEN and piggyBac 
transposons) and assisted reproduction technologies (such as somatic cell nuclear transfer 
or cloning) to create genetically engineered animal models of human diseases. The Wang 
laboratory is the first to succeed in developing gene-targeting tools in the golden Syrian 
hamster. Dr. Wang received his Ph.D. degree in molecular and cellular biology from 
University of Massachusetts at Amherst in 2000 and did his postdoctoral trainings at 
Massachusetts Institute of Technology. 
David Ayares, PhD, Revivicor Inc., USA 
S12: Genetically Engineered Pigs for Xenotransplantation 
David Ayares1, Todd Vaught1, Suyapa Ball1, Jeff Monahan1, Kasinath Kuravi1, Ben 
Morrill1, Amy Dandro1, Anneke Walters1, Steven Butler1, Lori Sorrells1, Kent Adams1, 
Maria Kokkinaki1, Jagdeece Ramsoondar1, John Bianchi1, and Carol Phelps1 
1Revivicor Inc, Blacksburg, Virginia, USA (a subsidiary of United Therapeutics) 
Genetic modification of the genome of pigs offers the opportunity to provide an unlimited 
supply of human-compatible xenograft donor organs, cells, and tissues for transplantation. 
Editing nucleases such as CRISPR/Cas9, combined with homology-driven recombination 
make gene knockout or knockin seem routine. Knockout of the α1,3-galactosyl transferase 
gene (GTKO) resulted in the elimination of hyperacute rejection  (HAR), and prolonged 
survival of xenografts in non-human primate studies. Employing a combination of cloning 
and breeding, next-generation GTKO pigs were produced with constitutive high-level 
expression of the complement regulatory genes, hCD46 and hDAF, that demonstrated 
strong inhibition of complement mediated cell lysis, while in vivo studies in non-human 
primates with islets and whole organs showed prolonged survival and function (over 6mo. 
for both islets and hearts) in the absence of antibody-mediated rejection. In order to 
overcome molecular incompatibilities in clotting factors between donor and recipients, 
human transgenes for inhibition of coagulation and thrombosis, including TFPI, 
thrombomodulin (TBM), EPCR and CD39, under endothelial cell-specific promoter 
systems, were added alone or in combination to produce donor pigs. Hearts from 
GTKO/hCD46/TBM transgenic pigs transplanted into baboons have maintained function 
for 900+ days, (with two others exceeding 1 year), demonstrating significant efficacy of 
these pig organ xenografts.  In addition, towards prevention of cell mediated rejection with 
reduced immuno-suppression, source pigs were produced which overexpress a dominant-
negative inhibitor of SLA class II (CIITA-DN), as well as genes to provide cytoprotection 
(HO-1 and A20), and immunomodulation (CD47).   Multi-cistronic “2A” vectors have 
facilitated the production of transgenic pigs with more than six genetic modifications, 
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where the added genes are not only co-expressed, but co-integrated in the genome, thus 
allowing propagation of new lines with reduced transgene segregation.  Tissues, cells, and 
organs from these multi-transgenic pigs have the potential to address virtually all levels of 
xenograft incompatibility, and should help drive outcomes that justify initiation of human 
clinical trials. 
David Ayares is executive vice president and chief scientific officer for Revivicor Inc. and 
leader of the team that cloned the world’s first pigs. Revivicor is a regenerative medicine 
company focused on a diverse pipeline of genetically engineered pigs as an alternative 
source of organs and tissues for human therapeutic use. Dr. Ayares was previously vice 
president of research and COO for PPL Therapeutics, and he worked for seven years in the 
pharmaceutical industry at Abbott Laboratories and Baxter Healthcare, developing 
transgenic mouse models for pharmaceuticals testing.  
Michael Cutler, DO, PhD, Intermountain Heart Institute  
S13: Translational Cardiovascular Research Utilizing Large Animal 
Genetic Engineering 
Michael J Cutler, DO, PhD1 
1Intermountain Medical Center Heart Institute, Intermountain Medical Center, 
Murray, Utah, USA  
Cardiovascular disease is the #1 cause of death worldwide and is a major public health 
problem.  Understanding the underlying mechanisms of cardiovascular disease is 
paramount to developing new and improved therapies to reduce the incidence of 
cardiovascular disease-related deaths. Significant advances have been made in our 
understanding of the cellular and molecular mechanisms of many aspects of cardiovascular 
disease using genetically altered small animal models. However, there are important 
limitations to translating these research findings to human medicine. This presentation will 
discuss the limitations of current small animal models and the potential benefits of large 
animal genetic engineering in advancing our understanding of the cellular and molecular 
mechanisms of cardiovascular disease. In particular, there will be special emphasis on the 
role of large animal genetic engineering in advancing these mechanistic insights into 
clinically meaningful therapies in humans. 
Michael Cutler is a heart rhythm specialist at the Intermountain Heart Institute and was 
previously an assistant professor of medicine at Case Western Reserve University. His 
research interests include understanding the cellular and molecular mechanisms of cardiac 
arrhythmia and gene therapy for cardiac arrhythmias. Dr. Cutler has received recognition 
from the American Physiological Society, American Heart Association and the Heart 
Rhythm Society for his work. 
20
Chris Rogers, PhD, Exemplar Genetics 
S14: TP53 and KRAS Targeted Pigs: A Platform for Models of Human Cancer 
Dawn Quelle1, Jessica Sieren2, David Meyerholz3, Benjamin Darbro4, Mahmoud Abou 
Alaiwa5, Carlos Chan6, and Christopher S. Rogers7 
1 Department of Pharmacology, University of Iowa, Iowa City, IA, USA; 2 Department of 
Radiology, University of Iowa, Iowa City, IA, USA; 3 Department of Pathology, University 
of Iowa, Iowa City, IA, USA; 4 Department of Pediatrics, University of Iowa, Iowa City, 
IA, USA; 5 Department of Internal Medicine, University of Iowa, Iowa City, IA, USA; 6 
Department of Surgery, University of Iowa, Iowa City, IA, USA; 7 Exemplar Genetics, 
Coralville, IA, USA  
We recently developed Yucatan miniature pigs with targeted TP53 mutations. Initial 
characterization reveals that 100% of TP53R167H/R167H mutant pigs develop cancer. 
These homozygous TP53 mutant pigs express two mutant alleles (R167H) of the p53 tumor 
suppressor in all tissues and are an outstanding model of osteosarcoma and B-cell 
lymphoma; however, the animals die from those tumors before other cancers can develop. 
By comparison, heterozygous TP53R167H/+ pigs are tumor-free after more than 2.5 years 
of age, though they are likely ‘primed’ for tumor development if other cancer genes are 
concomitantly altered. Our objective is to generate and characterize porcine cancer models 
in which tumorigenesis can be conditionally induced in specific tissues. We are particularly 
interested in lung and pancreatic cancers since they are among the deadliest and most 
difficult to diagnose malignancies in humans. A majority of human lung and pancreatic 
tumors are defined by the combined activation of oncogenic KRASand inactivating 
mutations of TP53 (typically on just one allele). Mouse models that replicate those genetic 
events by conditionally expressing TP53 and KRAS mutations in the lung or pancreas 
effectively develop cancers in those tissues. While informative, such small animal tumor 
models possess significant limitations and challenges for translational oncology. Large 
animals, such as pigs, share greater similarities with humans in anatomy, physiology, 
genetics, lifespan, and importantly, size. Therefore, we created dual targeted 
KRASG12D/+/TP53R167H/+ pigs which express one mutant allele of the TP53 gene as 
well as Cre-inducible mutant KRAS. We hypothesize that these conditional KRAS/TP53 
mutant pigs will produce site-specific cancers, as seen in comparable mouse models, 
providing much needed large animal tumor models for translational imaging, biomarker 
discovery, and pre-clinical testing of novel anticancer therapies. Studies are currently 
underway to establish the utility of the conditional KRASG12D/+/TP53R167H/+ pig model 
by defining optimal conditions for mutant KRAS induction and tumor development in the 
lung and pancreas. 
Chris Rogers is the chief scientific officer and co-founder of Exemplar Genetics, a 
company focused on the development and study of improved models of human disease. 
Dr. Rogers received his PhD from Vanderbilt University and completed post-doctoral 
training at the University of Iowa. While at Iowa, Dr. Rogers and colleagues created the 
first knockout and knockin models of a human disease in a large animal species - cystic 
fibrosis in pigs. At Exemplar Genetics, Dr. Rogers has directed the development and 
characterization of additional disease models including cancer, neurodegenerative disorders 
and cardiovascular diseases. 
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Timothy Sheets, PhD Student, University of Maryland 
S15: Investigating the Conserved Role of Neurogenin 3 (NGN3) in Endocrine 
Pancreatic Development in the Porcine Model Using CRISPR/Cas9 System    
Timothy P. Sheets1,2, Ki-Eun Park1,2, Anne Powell2, Steven Swift2, David M. Donovan2, 
Bhanu  Telugu1,2 
1Department of Animal and Avian Sciences, University of Maryland-College Park, MD. 
USA 
2Agricultural Research Services, Animal Bioscience and Biotechnology Laboratory, 
USDA, Beltsville, MD. USA 
The domestic pig is important as an agricultural and biomedical model species. The pig can 
serve as a complement to current mouse models, and in many cases, replace the mouse 
completely as a model for human disease. A failure to translate data generated from the 
mouse into human clinical trials limits the use of this model moving forward. The domestic 
pig is currently used in the medical device industry and by drug companies, due to its 
similar organ and vessel size to humans and the ability to model Adsorption Distribution, 
Metabolism and Excretion (ADME) studies. In the age of genome engineering and targeted 
gene therapy, the pig, can provide a longer life expectancy for disease progression, long 
term phenotypes and treatment end points. Using an example of ongoing disease modeling, 
the CFTR pig model not only surpasses the mouse models in comparative primary lung 
phenotype, but also recapitulates secondary phenotypes, specifically pancreatic agenesis 
leading to diabetes. In this study, we investigated whether the role of NGN3 is conserved 
across species. NGN3 is a member of the basic helix-loop-helix transcription factor family.  
In the mouse, Ngn 3 is both necessary and sufficient for the formation of endocrine 
pancreas during development. NGN3 is also believed to function in human endocrine 
pancreas development. In this study, we identified and amplified NGN3 from porcine BAC 
libraries. Once assembled, we designed guides to specifically target genomic sequence of 
NGN3 in the domestic pig for generating a knock-out. We injected a pre-complexed 
CRISPR/Cas9 protein and a NGN3-targeting sgRNA into porcine in vivo derived embryos; 
which were then transferred into synchronized surrogate animals. At day 63 of pregnancy, 9 
fetuses were harvested for genotypic and phenotypic analysis. Out of 9 piglets, 5 of them 
had biallelic mutations across the target site. RT-PCR data show loss of downstream genes 
in 3 of the biallelic mutants. Currently, we are confirming these data with IHC. Once the 
role of NGN3 is confirmed, we will investigate its role in transdifferentiation, converting 
exocrine cells to an endocrine lineage, and evaluate their efficacy in vitro and in vivo. 
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S16: Introduction of Callipyge Mutation into the Goat Genome Using 
Transcription Activator-like Effector Nucleases (TALENs) 
Min Yang1†, Dennis Webster2†, Qinggang Meng1, Zhiqiang Fan1, Daniel Carlson2, Misha 
Regouski1, Tracy Hadfield1, Christopher Bidwell3, Scott Fahrenkrug2, Noelle Cockett1 and 
Irina Polejaeva1 
1 Department of Animal, Dairy and Veterinary Sciences, Utah State University, Logan, UT, 
USA; 2 Recombinetics, Inc., Saint Paul, MN, USA; 3 Department of Animal Sciences, 
Purdue University, West Lafayette, IN, USA † Equal contribution  
The callipyge (CLPG) mutation arose in sheep in the 1980s with a phenotype of muscle 
hypertrophy and a novel inheritance mechanism of polar overdominance. The mutation is a 
single base, A to G transition, located within DLK1-DIO3 imprinted gene cluster. The 
regulatory mutation increases expression of several genes within the cluster. The aim of this 
study was to transfer the CLPG mutation into goats using TALENs and somatic cell nuclear 
transfer (SCNT). The desired adenine to guanine base change was introduced by  
co-transfection of TALENs and a single-stranded oligonucleotide was utilized as a template 
for homology directed repair. This strategy enabled production of homozygous and 
heterozygous cell clones for SCNT. CLPG cells were transferred into enucleated oocytes. 
Fused embryos were then activated for 5 min in 5 µM ionomycin followed by 4 h in 2mM 
DMAP with 5 µg/ml cycloheximide, cultured overnight and transferred into the oviducts of 
synchronized recipients. In total, 348 one-cell stage embryos were transferred to 21 
recipient goats. Three pregnancies went to term and four male offspring that carried 
homozygous CLPG alleles were produced. These goats would not be expected to exhibit 
muscle hypertrophy but may have altered gene expression. Biopsies of the longissimus 
dorsi were used to assess gene expression in the DLK1-DIO3 cluster (4 clones and 6  
age-matched controls). Gene expression was assayed for five loci (DLK1, CLPG1 and three 
maternal expressed long ncRNA) using RT-qPCR. There were no significant differences in 
gene expression between clones and controls. However, two clones had greater than 2-fold 
increase in the MEG3 levels and the other two clones had greater than 2-fold increased 
levels of DLK1 and much larger increases in CLPG1. The high variability in gene 
expression among the clones is likely due to incomplete reprogramming often observed 
following SCNT. These results demonstrate that TALENs and SCNT technologies can be 
efficiently used to introduce point mutations in goats. The muscle hypertrophy phenotype 
and regulatory effects of the goat CLPG allele will be tested by paternal transmission of the 
nascent allele to F1 progeny. 
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Session 6: Funding Mechanisms to Support Genetically Engineered 
Livestock Research, Presentations and Panel Discussion 
Moderator - Ken White, PhD, Utah State University, USA 
 
Ravi Ravindranath, DVM, PhD, NICHD, National Institutes of Health, USA  
 
Ravi Ravindranath is director of the Preimplantation Genetics and Development Program in 
the National Institutes of Health’s Reproductive Sciences Branch. He is responsible for 
grants related to oocytes, sperm, fertilization, preimplantation embryo development, 
embryonic stem cells, and germ cell development. His portfolio also includes grants related 
to cloning and reprogramming, preimplantation genetic diagnosis and Assisted 
Reproductive Technologies (ART). Following his doctorate in veterinary medicine and a 
M.S. in microbiology, Ravi earned a PhD in biochemistry from the Indian Institute of 
Science. He completed postdoctoral training at the University of Pittsburgh and the Clinical 
Research Institute of Montreal, Canada, before joining the Department of Anatomy and 
Cell Biology faculty at the Georgetown University Medical Center, Washington, D.C. He 
was an adjunct scientist in the Laboratory of Clinical and Developmental Genomics at the 
National Institute of Child Health and Human Development. His research background is in 
reproductive biology and endocrinology of rodents and nonhuman primates. 
 
Adele Turzillo, PhD, Director, Division of Animal Systems, USDA National 
Institute of Food and Agriculture, USA 
 
Adele provides leadership in the development, evaluation and management of a broad range 
of programs in research, extension and education. She is a primary point of contact for 
issues related to livestock production and serves as liaison to academia, the states, and 
several multistate projects. Adele also interacts with other federal agencies and serves as a 
scientific advisor on matters related to animal agriculture. 
 
Miguel Contreras, PhD, Program Officer, Division of Comparative Medicine, 
Office of Research Infrastructure Programs, National Institutes of Health, USA 
 
Miguel Contreras is a program officer with the Division of Comparative Medicine, Office 
of Research Infrastructure Programs, located within the Division of Program Coordination, 
Planning, and Strategic Initiatives, National Institutes of Health Office of the Director. He 
manages a research resource grant portfolio that includes aquatic and mammalian models 
and is program coordinator for the SBIR/STTR Small Business program. He is a biochemist 
at the Universidad de Concepcion, Concepcion, Chile. He received his PhD in molecular 
and cellular biology and pathobiology from the Medical University of South Carolina 
(MUSC), in Charleston. He was a Fogarty International Fellow at the Laboratory of 
Neurosciences, National Institute on Aging, NIH, in Bethesda, MD. Prior to joining ORIP, 
he was an assistant professor at the Charles Darby Children’s Research Institute and the 
Department of Pediatrics, College of Medicine, of the MUSC. His research focused on the 
mechanism of degeneration of the nervous system’s white matter in inherited metabolic 
disorders that affect peroxisomes and lysosomes (X-linked Adrenoleukodystrophy, Globoid 
cell leukodystrophy). 
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Session 7: Current and Future Large Animal Models in Biomedical 
Research 
Session Chair - Jon Oatley, PhD, Washington State University, USA 
Dr. Oatley’s studies the regulation of germline cell fate decisions in mammalian testis. His 
current research focus is on investigating the role of basic helix-loop-helix (bHLH) proteins 
in controlling spermatogonial stem cell fate decisions, the influence of non-coding small 
RNAs on establishment of the spermatogonial stem cell pool, and identifying growth 
factors produced by testis somatic support cell populations that contribute to the niche 
microenvironment. He directs Washington State University’s Center for Reproductive 
Biology. 
Eckhard Wolf, PhD, University of Munich Gene Center 
S17: Genetically Tailored Pig Models for Translational Diabetes Research 
Eckhard Wolf1,2, Andreas Blutke3, Rüdiger Wanke3, Simone Renner1,2  
1 Gene Center and Center for Innovative Medical Models (CiMM), LMU Munich, Munich, 
Germany  
2 German Center for Diabetes Research (DZD), Neuherberg, Germany  
3 Institute of Veterinary Pathology, Center for Clinical Veterinary Medicine, LMU Munich, 
Munich, Germany  
Diabetes mellitus (DM) has emerged into a steadily increasing health problem and the 
predicted future dimension of the global DM epidemic is alarming. Thus concerted research 
efforts are imperative to gain insight into disease mechanisms and to develop preventive 
and therapeutic strategies. Diabetic rodent models have limitations for translational 
research. Genetically engineered pig models may help to bridge the gap between basic 
research and clinical studies in (pre)diabetic patients (reviewed in [1]).   
The incretin hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-
like peptide-1 (GLP1) are secreted by enteroendocrine cells upon nutrient ingestion and 
stimulate insulin secretion. In type 2 diabetic patients the insulinotropic action of GIP is 
markedly reduced. To mimic this disturbance in a large animal model, we generated 
transgenic pigs expressing a dominant-negative GIP receptor (GIPRdn) under the control of 
rat Ins2 promoter sequences in the pancreatic islets (reviewed in [2]). GIPRdn transgenic 
pigs exhibit an impaired incretin effect due to a blunted insulinotropic action of GIP, a 
progressive deterioration of glucose control due to delayed and – at later stages – 
quantitatively reduced insulin secretion, and an impairment of physiological age-related 
expansion of beta-cell volume [3]. GIPRdn transgenic pigs thus provide a unique 
opportunity to screen for biomarker candidates during the pre-diabetic period [4] and to test 
therapeutic strategies targeting the GLP1 receptor [5].   
Missense mutations in the INS gene have been identified as common cause of insulin-
deficient, permanent neonatal diabetes mellitus in humans, also referred to as mutant INS 
gene-induced diabetes of youth (MIDY). We produced a transgenic MIDY pig line 
expressing INSC94Y under the control of the porcine INS promoter. MIDY pigs show 
early-onset clinical diabetes mellitus, markedly reduced body weight gain and beta-cell 
volume associated with a marked reduction of insulin secretory granules and severe dilation 
25
of the endoplasmic reticulum in the beta-cells [6]. MIDY pigs can be used for insulin 
treatment studies or for testing the efficacy of gene or cell therapies as well as islet 
transplantation. Secondary lesions of diabetes mellitus are another interesting area of 
research. We thus established the Munich MIDY pig biobank (highlighted in [7]) as a 
unique resource for studying systemic consequences of chronic hyperglycemia.   
References: [1] Renner et al., Theriogenology 86, 406-21 (2016); [2] Renner et al., J Pathol 
238, 345-58 (2016); [3] Renner et al., Diabetes 59, 1228-38 (2010); [4] Renner et al., 
Diabetes 61, 2166-75 (2012); [5] Streckel et al., J Transl Med 13, 73 (2015); [6] Renner et 
al., Diabetes 62, 1505-11 (2013); [7] Abbott, Nature 519, 397-8 (2015).  
Funding: German Center for Diabetes Research (DZD); German Research Council 
(Transregional Collaborative Research Center 127).  
Eckhard Wolf is director of the Laboratory for Functional Genome Analysis. He is the 
director of the Center for Innovative Medical Models, a member of the German National 
Academy of Sciences and corresponding member of the Austrian Academy of Sciences. 
Dr. Wolf is a leading specialist in the development of tailored animal models for 
translational biomedical research. 
Ann Harris, PhD, Feinberg School of Medicine, Northwestern University 
S18: Why Might New Large Animal Models of Cystic Fibrosis be Useful for 
Generating New Therapies? 
Ann Harris, PhD, Dept. Pediatrics and Lurie Children’s Research Center, Northwestern 
University, Chicago, IL. USA 
There are now many animal models of the common, inherited disorder cystic fibrosis (CF). 
These include multiple mouse strains, with various human pathogenic mutations on 
different genetic backgrounds; a rat; ferrets; rabbits and several mutant pig lines. Each of 
these models recapitulates some aspects of the human disease, but none accurately 
reproduces the complete human phenotype. Severity of disease in CF pigs, the most similar 
model to humans, presents additional challenges. These limitations are particularly relevant 
when considering the testing of new therapeutic strategies.  Here we consider what 
additional models could advance understanding of the CF phenotype and how they might 
contribute to attempts to find a cure for CF. 
Ann Harris is a professor in pediatrics and human molecular genetics at the Feinberg 
School of Medicine. Her primary research interest is elucidation of the regulatory 
mechanisms for the cystic fibrosis transmembrane conductance regulator (CFTR) gene, 
which when mutated causes the devastating inherited disease cystic fibrosis. 
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Noelle Cockett, PhD, Utah State University 
S19: Future Perspectives for Genetic Editing of Large Animals 
Noelle E. Cockett1  
1Department of Animal, Dairy and Veterinary Sciences, Utah State University, Logan, UT 
84322-1435 USA  
Opportunities for genetic editing in livestock exist in the areas of large animal biomedical 
models and improvement of livestock production.  While the generation of genetic edited 
animals is fairly straight forward, both areas are impeded by onerous regulatory processes 
that govern genetically modified animals. These regulations are primarily focused on the 
perceived dangers of consuming end products such as milk or meat of a genetically 
modified animal. Although large animals used as biomedical models are not intended for 
human consumption, the current regulations require containment to prevent the animal from 
moving into the food chain. In contrast, genetically edited production animals are intended 
for human consumption but pose no more risk to the consumer than any other production 
animals. In some cases, because of the genetic edit, animals will require less antibiotics 
and/or have reduced welfare issues, which are desirable outcomes for consumers.  
Given the innocuous methods that now exist for genetic editing, the focus of regulation 
should move from the process of generating the animal to a review of the resulting animal. 
Refocusing regulation requirements will substantially reduce the cost of genetically edited 
animals. However, an additional cost is added to the large animal biomedical model, which 
is the need for the model to be validated using a collection of clinical phenotype 
measurements. It is unlikely that researchers will use a large animal model without that 
validation.    
Noelle Cockett currently serves as Utah State University’s executive vice president and 
provost, and is a professor in the Department of Animal, Dairy and Veterinary Sciences. 
She has built a career in sheep genetics research, specializing in molecular genetics and 
identifying genetic markers. Dr. Cockett is known for being part of the research team that 
successfully sequenced the ovine genome.  
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P1: A Simple and Efficient Vitrification Procedure for Cryopreserving Mouse Embryos and 
Oocytes Using Plastic Semen Straws 
Mo Guan, Martin Fray 
Medical Research Council, Mary Lyon Centre, Harwell Campus, Oxfordshire, OX11 0RD, UK 
Vitrification is a freezing method in which cells and media are solidified without ice crystal 
formation. Consequently, injuries related to ice formation are less likely to occur. To achieve 
success in vitrification, high cooling rates and high concentrations of solutes are commonly 
believed to be necessary. However, to reduce the toxicity of the vitrification solutions and to 
achieve a high cooling rate, a minimum time in the vitrification solution and a minimum volume 
of vitrification solution are thought to be essential. However, these requirements make 
embryo/oocyte handling difficult during the vitrification, and subsequent warming procedures. 
Compared with other vitrification methods, the DAP213 vitrification method is simple and 
efficient, and only requires a brief two-step exposure of embryos/oocytes to the vitrification 
solution prior to plunging directly into liquid nitrogen. However, this method has traditionally 
used a specific type of vial as the sample carrier, which is not compatible with many laboratories 
which use plastic semen straws as their preferred storage system. 
At the MRC we have developed an aluminium cooling plate for vitrification in straws. The 
cooling plate ensures stable refrigeration at 0°C during the equilibration process. In the 
experiments reported here, 2-cell embryos from C57BL/6N Tac mice were used. For 
comparison, embryos were vitrified in straws (n=3) and vials (n=3) using DAP213 as 
vitrification solution. The viability of vitrified embryos was compared in terms of post-warming 
survival rate, as well as their in vitro and in vivo developmental rates. The results demonstrated 
that there is no significant difference between straws and vials in survival rate (97.14 ± 2.86 vs 
98.10 ± 0.95), development to blastocyst (94.74 ± 2.90 vs 84.48 ± 6.16) and birth rate (43.33 vs 
46.67). These results indicated that the DAP213 vitrification procedure can be adapted for use 
with straws which are cheap to buy and compatible with space saving bulk tank storage systems. 
This method can also be used for oocytes vitrification. 
Keywords: vitrification, mice, embryo, oocyte 
P2: Derivation of Extra-Embryonic Endoderm Cells from Preimplantation Pig Blastocysts 
Chi-Hun Park1,2, Anne Powell2, David M. Donovan2, Bhanu P. Telugu1,2 
1Department of Animal and Avian Sciences, University of Maryland, College Park, MD, 
USA; 2Animal Bioscience and Biotechnology Laboratory, USDA-ARS, Beltsville, MD, USA 
In the fertilized mammalian embryo, the development of blastocyst marks the first visual cell 
fate decision. In the blastocyst, the precursor cells for placental extraembryonic membranes 
called the trophectoderm (TE) line the outside of the embryo, whereas, the cells on the inside 
aptly called the inner cell mass (ICM) give rise to the fetus proper. Following this first lineage 
differentiation event, a group of cells from the ICM also give rise to the primitive endoderm cells 
(PrE) that line the inside of the fluid filled blastocoel cavity forming the yolk sac. In culture, the 
blastocyst stage embryos give rise to characteristic lines derived from the TE, ICM and PrE. 
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Here we describe the establishment and characterization of extraembryonic endoderm (XEN) 
cell lines derived from PrE of day 7 pre-implantation pig blastocysts. In vitro generated porcine 
D7 blastocysts were explanted onto irradiated mouse embryonic fibroblasts in DMEM medium 
supplemented with 15% fetal calf serum (FCS), leukemia inhibitory factor (LIF), and basic 
fibroblast growth factor (bFGF). After 2 days of culture, three types of cell outgrowths as 
evidenced by morphology and the expression of lineage-specific markers were identified. A 
cluster of cells with compact morphology and likely derived from the epiblast (Epi) expressed 
key pluripotent markers (e.g. NANOG, and SOX2), whereas the other two cell types that 
exhibited a cobble-stone morphology expressed markers of TE-specific genes (CDX2) or PrE-
(GATA4 and GATA6). Following initial establishment, Epi and TE cells have mostly 
disappeared during further subculture, whereas XEN cell colonies expressing GATA factors 
grew rapidly and were continuously cultured for over 30 passages. These cells showed high level 
of SALL4 expression, which contributes to the regulation of stemness of XEN cells, but not 
AFP, which is a visceral endoderm marker. Its proliferation was dependent on feeder cells with 
either LIF or FGF signal molecules. In summary, we demonstrated that the XEN cell lines from 
day 7 pig blastocysts can be reproducibly derived and the morphological and molecular 
characteristics of these cells are similar to mouse XEN cells. However, further studies are needed 
to determine whether pig XEN cells fulfill the requirement of typical XEN cells features. 
P3: Disruption of CFTR Gene in Sheep Fibroblast Cells Using CRISPR/Cas9 Approach 
Zhiqiang Fan1, Zhongde Wang1, Iuri V. Périssé1, Min Yang1, Misha Regouski1, Ann Harris2, 
Kenneth L. White1, Irina A. Polejaeva1 
1 Department of Animal, Dairy, and Veterinary Sciences, Utah State University, Logan, 
UT 84322, USA; 2 Department of Pediatrics, Northwestern University Feinberg School of 
Medicine, Chicago, IL 60614, USA.  
Cystic Fibrosis (CF) is a common life-shortening, autosomal recessive disease in Caucasian 
populations that affects approximate 1 of every 2500 newborns. The CF gene was identified as 
the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) encoding a conductance 
chloride anion channel. Sequence analysis of CFTR shows 90% similarity at the nucleic acid 
level and 95% at the polypeptide level between sheep and human. A sheep model of CF is likely 
to be beneficial in investigating CF pathogenesis and furthering pharmacological approaches to 
the treatment of CF. Here, we report the successful application of the CRISPR/Cas9 system to 
disrupt CFTR in sheep fibroblast cells, which can be used for the production of cloned sheep by 
Somatic Cell Nuclear Transfer (SCNT). We designed 5 single-guide RNAs (sgRNAs) specific 
for CFTR: 2 for exon 2 and 3 for exon 11. The targeting vectors were constructed by using 
pX330 plasmid and transfected into 2 x105 male fetal fibroblast cells. The gene mutation 
efficiency of each targeting vector was determined by PCR/RFLP assay 3 days post transfection. 
Our results showed that 2 sgRNAs, 5’- GAAAGGATACAGACAGCGCT – 3’ for exon 2 and 5’ 
–GGGAGAATTGGAACCTTCAG – 3’ for exon 11, were highly efficient in directing Cas9 to
generate targeted cleavages in CFTR, with mutation efficiencies of 18.5 % and 40.9 %,
respectively. Sequencing analysis of PCR products showed that typical nucleotide insertions and
deletions, caused by repairing double-strand DNA breaks during the error-prone non-
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homologous end joining process, were generated in each of the targeted CFTR loci. We also 
isolated single cell-derived sheep fetal fibroblast colonies by limiting dilution following 
transfection. The colony screening with the PCR/RFLP assay confirmed that we achieved 
targeted gene disruption in 10/51 (19.6%) colonies for exon 2 (5 colonies with biallelic and 5 
with monoallelic CFTR gene disruption), and in 17/49 (34.7%) cell colonies for exon 11(13 with 
biallelic and 4 with monoallelic). In conclusion, we demonstrate that CRISPR/Cas9 is a highly 
efficient system for generating targeted mutations in CFTR gene in sheep fetal fibroblasts. These 
cells will be subsequently used for SCNT to generate sheep models of CF. 
P4: DNA Methylation and Gene Expression Levels in Hypothalamus and Ovary of Capra hircus 
Across the Genome 
Stefano Frattini1, Barbara Lazzari2,3, Emanuele Capra2, Andrea Talenti1, Beatrice Coizet1,  
Stephanie D. McKay4, Alessandra Stella2,3, Giulio Pagnacco1, Paola Crepaldi1 
1 Department of Veterinary Medicine, University of Milan, Milan, Italy; 2 Institute of 
Agricultural Biology and Biotechnology, National Research Council UOS of Lodi, Lodi, Italy; 
3PTP - Science Park, Lodi, Italy, 4 Department of Animal & Veterinary Sciences University of 
Vermont, Burlington, VT, USA 
Hypothalamus and ovary are two key organs of the female reproduction system of mammals. 
Their role in controlling ovulation is well known, but the epigenetic mechanisms behind it, such 
as DNA methylation, remain unclear. Goats are an important source of milk, meat and fiber, 
especially in developing countries. Despite this, among economically relevant livestock species, 
they are still poorly investigated from a genomic point of view. The aim of this work is to find a 
relation between expression levels and methylation levels, in order to understand how 
methylation peaks in different gene regions affect gene expression in goat hypothalamus and 
ovary. Genome-wide methylated CpG detection and gene expression analysis in hypothalamus 
and ovary of three adult Saanen goats were performed. Animals in the study were managed 
according to the existing European Directive 2010/63/EU on the protection of animals used for 
scientific purposes. For the methylome analysis DNA binding domain sequencing (MBD-seq) 
with enrichment of methylated DNA fragments was performed. Gene expression was evaluated 
by RNA-Seq analysis. Sequencing was accomplished with Hiseq 2000 Illumina. Around 23-37 
million raw sequencing reads were generated from each sample for the methylome analysis. 
Methylation distribution was investigated in six different genomic regions: promoter, intron, 
exon, downstream of gene, distal and intergenic. Matching the methylation pattern in 
hypothalamus and ovaries in contrast to their transcriptome allowed the identification of genomic 
regions in which methylation peaks most affect gene expression. Hypothalamus showed a highly 
significant negative correlation (P<0.001) between methylation peaks in promoter and in 
downstream regions and gene expression. A positive correlation (P<0.001) was observed within 
exons. Conversely, ovary did not show any significant consistent correlation between gene 
expression and methylation. This work provides evidence for a clearer understanding of the 
epigenetic mechanisms underlying gene regulation. A more accurate annotation of the goat 
genome will be necessary for a deeper insight in the role of DNA methylation in gene expression 
in Capra hircus, a candidate model species for other mammals. 
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P5: Effect of Neuromedin U on Pig Immune Regulation 
Xiang Li, Xiaoliang Li, Wenna Qiao, Zhiyu Ma, Juan Su, Zhihai Lei 
College of Veterinary Medicine, Nanjing Agricultural University, Nanjing, Jiangsu, P.R. China 
Neuromedin U (NMU) is a conserved mammalian neuropeptide discovered in the 1980s, and 
found in two forms, NMU-25 and NMU-8. Wide distribution of NMU in animal organs suggests 
that NMU is involved in multiple physiological functions, including immune regulation. 
However, the role of NMU in pig immune regulation has not been reported. To study the effect 
of NMU on pig immune regulation, we cloned and detected the expression of NMU and its 
receptors in pig lymphatic organs and immune cells. We also investigated the effect of NMU on 
cytokine secretion after injection of (0, 5, 15, 45 nmol) NMU into the intracerebral ventricle 
(i.c.v) of 16 pigs (n=4 for each group), and the effect of (0.1～1000 nM) NMU on cytokine 
secretion in cultured dendritic cells and natural kill (NK) cells using ELISA and RIA methods. 
The results were as follows: 1) NMU and its receptors were expressed in lymphatic organs, 
cultured dendritic cells and NK cells. 2) NMU stimulated IL-1β, IL-6, IL-8, TNF-α and IL-10 
secretion (P＜0.05) post-injection in a time- and dose-dependent manner, compared with the 
control group. 3) NMU increased IL-8, IL-6 and IL-13 secretion and reduced IL-10 secretion (P
＜0.05) in cultured dendritic cells. 4) NMU enhanced the killing activity of cultured NK cells, 
stimulated IFN-γ secretion and inhibited IL-10 secretion (P＜0.05) in NK cells in a time- and 
dose-dependent manner. This study suggests that NMU has the role in pig immune regulation 
through its effect on cytokine secretion and increasing killing activity of NK cells. Key words: 
NMU, Pig, NK cell, Dendritic cell, cytokine, immune regulation 
P6: Effect of Unbalanced Pedigree on Genetic Evaluation in Tunisian Holstein Cows 
Yosra Ressaissi1, M. Ben Hamouda2  
1Departement des Sciences Animales, Institut National Agronomique de Tunisie, 43 Avenue 
Charle Nicolle 1082-Tunis-Mahrajène-Tunisie. 2Institut National de recherches agronomiques de 
Tunisie, Rue Hédi Karray-2049 Ariana Tunis.  
The pedigree quality was tested on the genetic evaluation process using 3 files. The first file was 
the original one which included the whole cows from which two extra pedigrees were generated: 
a file with only cows whose mothers are known and a file with only cows who’s both parents are 
known. A uni-trait animal model was fitted to 305-day dairy records (MY305) and counting on 
the restricted maximum likelihood procedure, the construction of the entire relationship matrix 
between cows and their ancestors was considered. The correlations of Pearson (r) and the 
distribution of the genetic deviation by flocks were made to appreciate relationship between the 
breeding values and to estimate genetic diversity according to the available genealogical 
information. Heritabilities were around 0.15 and 0.39 and genetic correlations have varied from 
0.82 to 0.94. Using the balanced pedigrees, the genetic parameters were ameliorated and the 
coefficients of correlation were all positive while they were found to be higher between the 
predicted values using the balanced pedigrees. The distribution of the genetic variability was 
different according to the used pedigree. The heterogeneity in animal identification generates an 
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unbalanced pedigree of poor quality which penalizes the appropriate combination of the 
performances with the genealogical information. Consequently, the relevance of genetic 
evaluation and the estimation of genetic variability will be affected. 
P7: Establish of Immortalized Cell Line for Improving the Production Efficiency of the 
Disease-model Pigs 
Seon-Ung Hwang1,2, Junchul David Yoon1,2, Kiyoung Eun3, Hyunggee Kim3,* and Sang-  Hwan 
Hyun1,2* 
1Laboratory of Veterinary Embryology and Biotechnology, Veterinary Medical Center and 
College of Veterinary Medicine, Chungbuk National University, 1 Chungdae-ro, Seowon-gu, 
Cheongju 28644, Republic of Korea; 2Institute of Stem Cell & Regenerative Medicine, 
Chungbuk National University, 1 Chungdae-ro, Seowon-gu, Cheongju 28644, Republic of 
Korea; ³Department of Biotechnology, School of Life Sciences and Biotechnology, Korea 
University, Seoul 02841, Republic of Korea.  
Production efficiency of disease-model pigs using somatic cell nuclear transfer (SCNT) is very 
low. It is probably because of senescence and the characteristics of the transgene. These make 
limitations in a pregnancy and a production of disease-model pigs. In this study, we introduce 
SV40LT oncogene into the fibroblast cells in order to establish immortalized transgenic cell line 
for producing the disease-model pigs. As a result, SV40LT cell lines showed that, even though a 
high passage, the normal cell morphology was observed with active cell division. We then 
evaluated the effect of SV40LT oncogene on transgenic SCNT embryo development. The 
cleavage rates (73.8±4.0 and 48.6±2.4 in the normal and SV40LT group, respectively; P<0.05) 
and blastocyst formation rates (19.5±1.2 and 5.6±1.8 in the normal and SV40LT group, 
respectively; P<0.05) of transgenic SCNT embryos was significantly lower than the case of using 
normal cells. In conclusion, the SV40LT inserted cell line showed active proliferation in the 
fibroblast state. However, that is not suitable for somatic cell nuclear transfer. To overcome this, 
the introduction of the induction system in cell lines, such asecdysone-inducible gene switch, 
tetracycline-inducible system and Gal4/UAS system, is required to increase the production 
efficiency of the disease-model pigs. Keywords: Porcine, SCNT, SV40LT 
This work was supported, in part, by a grant from the "Cooperative Research Program for 
Agriculture Science & Technology Development (Project No. PJ011288, PJ011077)", and the 
"Ministry of Trade, Industry & Energy(MOTIE), Korea Institute for Advancement of 
Technology(KIAT) through the Leading Industry Development for Economic Region (Project 
No. R0004357)", Republic of Korea. 
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P8: Expansion and Differentiation of Isolated Porcine GFAP-CreERT2 Neural Stem Cells Using 
Neurosphere Assay  
 
 
Eunhye Kim1, Hyunggee Kim2 and Sang-Hwan Hyun1,* 
1Institute for Stem Cell & Regenerative Medicine (ISCRM), Chungbuk National University 
& Laboratory of Veterinary Embryology and Biotechnology (VETEMBIO), College of 
Veterinary Medicine, Chungbuk National University, Cheongju, Republic of Korea; 2School of 
Life Sciences and Biotechnology, Korea University, Seoul, Republic of Korea 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
In this study, we used the neural stem cells (pGFAP-CreERT2-NSCs) from the transgenic piglet 
with expression of CreERT2, a fusion protein of the DNA recombinase Cre and mutated ligand-
binding domain of the human estrogen receptor, under the control of the GFAP promoter. The 
primary culture from tissue of porcine CreERT2 brain led to floating spherical masses of cells 
and quantitative analysis indicated a yield of 2.50±0.44 primary spheres per 1,000 viable cells 
from the neocortex, versus 12.92±1.67 primary spheres per 1,000 viable cells from the 
periventricular region (PVR) including subventricular zone (SVZ). Secondary spheres 
(6.67±1.10 spheres from neocortex versus 23.08±1.96 spheres from PVR cells) were formed 
from primary spheres at 10 days after passage. Tertiary spheres (8.42±0.99 spheres from 
neocortex versus 23.08±1.91 spheres from PVR cells) could also be obtained after a second 
passage indicating that they were proliferating in vitro. The CreERT2-NSCs showed normal 
36+XY karyotype with all analyzed metaphases free of any discernable cytogenetic 
abnormalities and representative NSC markers such as NESTIN, SOX2 and VIMENTIN. After 
differentiation, we were able to obtain populations of astrocytes and neurons expressing GFAP 
and TUJ1, respectively. Although further studies will be needed, we developed a novel platform 
for expansion and neural commitment of the isolated GFAP promoter-driven CreERT2-NSCs 
which would be considered a useful tool for study of central nervous system diseases. 
This work was supported, in part, by a grant from the “Cooperative Research Program for 
Agriculture Science & Technology Development (Project No. PJ011288, PJ011077)", the 
Ministry of Trade, Industry & Energy (MOTIE), Korea Institute for Advancement of 
Technology (KIAT) through the Leading Industry Development for Economic Region 
(Project No. R0004357)“ and “Korea Institute of Planning and Evaluation for Technology in 
Food, Agriculture, Forestry and Fisheries (IPET) through Advanced Production Technology 
Development Program, funded by Ministry of Agriculture, Food and Rural Affairs (MAFRA) 
(Grant number: 115103-02)”, Republic of Korea. 
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P9: Four Years of Editing the Livestock Genome 
Chris Proudfoot1, Simon G Lillico1, Christine Burkard1, Wenfang Tan1, Maeve Ballantyne1, 
Claire Neil1, Scott C. Fahrenkrug2, Fyodor D. Urnov3, Alan J. Mileham4, Alan L. 
Archibald1 & C. Bruce A. Whitelaw1. 
1 The Roslin Institute and R(D)SVS, University of Edinburgh, Easter Bush Campus, 
Edinburgh, EH25 9RG, UK; 2 Recombinetics Inc, 2575 University Ave. West, Suite 100, Saint 
Paul, MN 55108, USA; 3 Sangamo BioSciences, Point Richmond Tech Center, 501 Canal 
Boulevard, Suite A100, Richmond, CA 94804, USA; 4 Genus plc, 1525 River Road, DeForest, 
WI 53532, USA.  
Recent advances in genome engineering have produced a range of tools that allow the precise 
modification of livestock genomes. Microinjected directly into the newly fertilised zygote, 
genome editor reagents are proving to be a very effective methodology for inducing changes in 
the DNA sequence at their target sites, opening up a multitude of options for genome 
manipulation. This ability to modify the genome, without the necessity of transgene insertion, 
allows the production of animals with designer traits such as improved disease resistance, 
enhanced production values or as models of human disease. We present data detailing our 
experiences with TALENs, ZFNs and CRISPR/Cas9 to induce NHEJ, HDR or deletion events in 
either sheep or pigs. 
P10: Identification of Transgene Insertion Sites by Target Selection and Next-Generation 
Sequencing 
Aaron J. Thomas1,2, Rousselene Jones1, Misha Regouski2, Irina Polejaeva2, Christopher J.  
Davies1,2 
1 Center for Integrated BioSystems, Utah State University, Logan, UT, USA; 2 Department of 
Animal, Dairy and Veterinary Sciences, Utah State University, Logan, UT, USA  
Atrial fibrillation is a serious cardiac arrhythmia for which better large animal models are 
needed. A transgenic goat expressing constitutively active Transforming Growth Factor-β 
(TGF-β) in the heart was created by random insertion of a construct containing the mouse α-
Myosin Heavy Chain promoter driving expression of a constitutively active human TGF-β gene. 
Subsequent breeding of this female goat and clones of the founder animal produced three male 
offspring that tested positive for the transgene. To identify the transgene insertion site(s), we 
constructed sequencing libraries from genomic DNA of these goats and subjected them to target 
selection using RNA baits made from the transgene construct. The resulting libraries were then 
sequenced on the 454 GS FLX+. The sequence reads were aligned to the goat genome and to the 
transgene construct to identify those reads that had both goat genomic sequence and insert 
sequence. Two insertion sites were identified: one in the RASAL2 gene on chromosome 16 and 
one in the ULK4 gene on chromosome 22. Reads from the insertion site on chromosome 16 all 
mapped to only one end of the insertion site whereas reads from both ends of the insertion site on 
chromosome 22 were found. This is an effective method to find the genomic location of 
transgenes inserted by random insertion or to find off-target insertion events when targeted 
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insertion methods are used. The insertion site sequence information was used to design PCR 
primers that can be used to screen offspring of the clones to determine whether they carry one or 
both chromosomes with the TGF-β transgene. 
P11: Impact of Histone Acetylation Status on the In Vitro Development of Porcine Transgenic 
Cloned Embryos 
Biping Luo1,2, Shiqiang Ju1, Rong Rui1 
1 College of Veterinary Medicine, Nanjing Agricultural University, Nanjing, Jiangsu 210095, 
China; 
2 College of Animal Science & Technology, Jinling Institute of Technology, Nanjing, Jiangsu 
210038, China 
Transgenic cloning is a modern biotechnology combined transgenesis with nuclear transfer. 
Around 20 years have been passed after the birth of that famous cloned sheep “Dolly”. The 
somatic cell nuclear transfer used for the production of Dolly enables it possible to produce 
transgenic pigs. However, the efficiency to produce transgenic cloned pigs is at low level to date. 
Many factors impact on the development of transgenic cloned embryos, including epigenetic 
modifications. The purpose of this study was to investigate the effects of histone deacetylase 
(HDAC) inhibitor trichostatin A (TSA) on transgene expression and development of porcine 
transgenic cloned embryos, specifically, focusing on effects derived from TSA-treated donor 
cells or TSA-treated reconstructed embryos. The results showed that TSA treatment on 
reconstructed embryos modified the acetylation status, which significantly improved the 
development of porcine somatic cell nuclear transfer (SCNT) embryos in vitro, but not donor 
cells. Furthermore, the treatment of reconstructed embryos with TSA enhanced expression of the 
pluripotency-related gene POU5F1 and stimulated expression of the anti-apoptotic gene Bcl-2. 
Enhanced green fluorescent protein (EGFP) mRNA expression of every group dropped 
drastically from donor cells to blastocysts. Interestingly, TSA is likely to prevent a decline in 
EGFP expression in nuclear reprogramming of porcine SCNT embryos. However, DNA 
hypomethylation induced by modified histone acetylation of donor cells treated with TSA was 
significantly more effective to increase EGFP expression in SCNT blastocysts. In conclusion, 
acetylation status of both donor cells and reconstructed embryos modified by TSA treatment 
increased transgene expression and improved nuclear reprogramming and developmental 
potential of porcine transgenic SCNT embryos. 
Keywords: acetylation status; development; transgene expression; TSA; EGFP; SCNT; pig 
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P12: Integration of Molecular Imaging and Transgenesis for Developing Large Animal Models 
Liaohai Chen1, Irina Polejaeva2, and Zhongde Wang2  
1Department of Surgery, University of Illinois at Chicago, 2Animal, Dairy, and 
Veterinary Sciences Department, Utah State University, Logan, UT 
Humane use of large animal models plays a critical role in understanding disease etiology and 
developing therapeutics. With the significant advances in gene targeting and somatic cell nuclear 
transfer, it is now feasible to produce a transgenic large animal with a latent transgene(s) 
embedded in its genome. However, large animals have a longer lifespan, and the impact of 
activated transgene(s), as well as the appearance of disease phenotype, may take a long time to 
manifest. The integration of molecular imaging with transgenesis enables the reveal of activation 
efficiencies, when, where, and the expression level of the transgene product(s). Otherwise, 
questions on whether the transgene is activated in the target organ and/or whether the transgene 
functionally contribute to the symptom/disease phenotype will require invasive surgical 
procedures or sacrifice of the animals, which will greatly hinder the development of large animal 
models. In addition, the ability to evaluate pharmacologic parameters through imaging on large 
animals will significantly lower the expense and the numbers of animals needed for the pre-
clinical studies. Recently, we used somatic cell nuclear transfer (SCNT) method to develop 
mutated human K-ras transgenic goats as a potential large animal tumor model. Newborn kids 
have been confirmed to bear activable K-ras oncogene (K-rasG12D) and herpes simplex viral 
thymidine kinase HSV-tk gene, a well-established reporter gene. The presence of the report gene 
will enable imaging the effectiveness of K-ras activation, K-ras location/expression level upon 
activation in transgenic goats by Positron Emission Tomography (PET). In vitro experiments 
have confirmed the transformation from normal cells to tumor cells once the transgenes were 
activated.  A clinical PET-CT system is being installed at USU.   
P13: In Vivo Ovarian Germ Cell Transgenesis 
Rhett L. Peterson, Kate C. Parkinson and Jeffrey B. Mason  
Department of Animal, Dairy and Veterinary Sciences, Center for Integrated BioSystems, 
School of Veterinary Medicine, Utah State University, Logan, UT, USA. 
In somatic gene transfer, the recipient's pattern of gene expression is changed, but the change is 
not passed on to the next generation. In germline gene transfer, the germline cells are changed 
with the goal of passing on the changes to offspring. We are currently investigating in vivo gene 
transfer to ovarian tissues (somatic and germline) using recombinant adeno-associated viral 
vectors. Our objectives are to 1) alter ovarian gene expression in vivo to modify the influence of 
the ovaries on the physiology of the recipient and 2) to use this technology to produce germline-
transmissible changes in livestock species. What makes this work unique is that we are altering 
genetic influence focally (ovaries) in an otherwise normal, adult animal and these changes will 
be germline-transmissible. Adult, six-month-old female CBA/J mice had their ovaries surgically 
exposed to a eGFP-containing recombinant adeno-associated virus. Four weeks postoperatively, 
the females were induced to ovulate and the entire reproductive tract was collected. Ovaries were 
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routinely processed for histology using an anti-eGFP antibody. Ovulated oocytes were evaluated 
for eGFP expression at the time of collection. Ovulated oocytes and histological ovary sections 
both displayed evidence of eGFP transgene expression. Adeno-associated viral vectors normally 
remain episomal in transduced cells. However, transduced oocytes, upon fertilization will 
undergo meiosis exposing the 'normally episomal' transgene to meiotic recombination, similar to 
the process that allows incorporation of genes using oocyte/zygote microinjection. Future work 
will include in vitro fertilization of transduced oocytes, breeding of recombinant adeno-
associated viral vector-exposed female mice and intra-ovarian transduction of ovaries in sheep. 
P14: Large Exotic Animal Models for Heritable Neurological Disease and Cancer 
Brian W. Davis, Ph.D. 
Cancer Genetics and Comparative Genomics Branch, National Human Genome 
Research Institute, National Institutes of Health; Bethesda, Maryland, USA. 
The expanding field of high throughput genomics has allowed the exploration of other model 
system for the identification of loci implicated in disease.  Natural models for the study of 
genetic conditions are underway in felines and canines, as well as agricultural species.  The 
population structure and veterinary surveillance of these organisms under human care lend 
themselves very well to understanding the mechanisms that underlie common conditions shared 
with humans.  Recently, using RNAseq, our work has shown that canine transitional cell 
carcinoma, which has orders of magnitude higher occurrence of in certain canine breeds, shares a 
common somatic mutation (BRAF V600E) with several human cancers. An extension of this 
work is being explored for two conditions in exotic cats, which share similar population 
bottlenecks and veterinary surveillance as companion animals. In addition, their extended age in 
captivity (oten twice that of the wild) aids in understanding disease associated with geriatry. Our 
data shows malignant melanoma is prevalent in the captive tiger population, but is enriched in 
certain breeding lines.  The same is true for spinocerebellar ataxia in African lions, which is 
linked to hypovitaminosis A, regardless of diet.  Using whole genome and transcriptome 
sequencing in collaboration with the Exotic Genome Repository (exoticgenome.org), we propose 
a model that incorporates populations maintained in zoological parks with generational health 
and breeding records as a proxy for human health.  This not only provides mechanisms for 
testing human therapies in these species, as exemplified by canines, but allows the application of 
previously identified, targeted human therapies for use in these animals. 
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P15: Management of Many Recessive Disorders in a Dairy Cattle Population Using Gene 
Editing and Sequential Mate Allocation 
John B. Cole 
Animal Genomics and Improvement Laboratory, Agricultural Research Service, United States 
Department of Agriculture, Beltsville, MD, USA  
High-density single nucleotide polymorphism genotypes have recently been used to identify a 
number of novel recessive mutations that adversely affect fertility in dairy cattle, as well as to 
track conditions such as red coat color and polled. Recent findings suggest that the use of 
sequential mate allocation strategies that account for increases in genomic inbreeding and the 
economic impact of affected matings result in faster allele frequency changes than strategies 
which do not consider inbreeding and monetary losses. However, the effect of gene editing on 
selection programs also should be considered because gene editing has the potential to 
dramatically change rates of allele frequency change. A simulation program developed to 
evaluate dairy cattle breeding schemes was extended to include the use of CRISPR-Cas9, 
TALEN, and ZFN for gene editing. A hypothetical technology with a perfect success rate was 
used to establish an upper limit on attainable progress, and a case with no editing served as a 
baseline for comparison. The technologies differed in the rate of success of gene editing, as well 
as the success rate of the embryo transfer step, based on estimates in the literature. For purposes 
of this study the number of alleles edited had no effect on success rate. The two scenarios 
evaluated considered only the horned locus, or 12 recessive alleles currently segregating in the 
US Holstein population. The top 1, 5, or 10 % of bulls were edited each generation, and either no 
cows or the top 1 % of cows were edited. Cumulative genetic gain did not differ across scenarios 
because the elite animals in the population were the ones selected for genetic modification. Gene 
editing was very effective at reducing the frequency of the horned haplotype (increasing the 
frequency of polled animals in the population), and allele frequencies of the 12 recessives 
segregating in the US Holstein population decreased faster with editing than without. These 
results suggest that gene editing is an effective tool for reducing the rate of harmful alleles in a 
dairy cow population even if only a small proportion of elite animals are modified. 
P16: MedSwine: Engineering Swine Genome for Biomedical Models 
Bin Zang1, John Garbe2, Dan Carlson4, Scott Fahrenkrug3,4 
1Scientific computation, University of Minnesota, 200 Union St, Minneapolis, MN 55455, USA. 
Minnesota Supercomputing Institute, University of Minnesota, 117 Pleasant St SE, Minneapolis, 
MN 55455, USA; 2Department of Animal Science, University of Minnesota, 1364 Eckles Ave, 
Saint Paul, MN 55108, USA; 3,4Recombinetics, Inc., 1246 University Avenue W, #301, Saint 
Paul, MN 55104, USA  
Large Animals Better Resembles Human Disorders 
We firstly compared several model animals including mice, rats, zebrafish as well as pigs to find 
out the resemblance of human disorders with known disease-gene relationship. By measuring the 
proteome level similarity of gene sets that are related to different disorder types, we identified 
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disorders in human that can be better modelled with large animals, especially pigs, than murine 
models. We find that these disorders include human metabolic syndromes such as MODY, and 
certain cancer types, such as breast cancer and liver carcinoma. 
Imputing Human Disease-causative Mutations in Pig Genome 
We collected variations presented in human genome with clinical significance from OMIM 
curated disease associated genes, of which, 5,916 have been successfully annotated in current pig 
genome assembly. We used protein alignment of the corresponding orthologous gene pairs to 
annotate potential editing sites within the pig genome. Overall, we imputed 947 nonsynonymous 
stop gained deletions, leading to partial/complete loss of function mutations, as well as 4,330 
missense mutations in human genome to have corresponding pig edit sites. This result enables us 
to edit the pig genome for the model of 2,484 human disorders with at least one confirmed 
associated SNP. 
In silico Off-target Prediction of Editing Tools 
Rise of genome editing tools such as CRISPRs and TALENs gave us power to easy editing the 
genome. With pre-computed nucleases, we identified 5,363 CRISPRs sit nearby a disease 
associated SNP site. Among all these CRISPRs 1,603 of them sits within 20bp range of the SNP, 
indicating a set of good target candidates for human disease model. 
MedSwine as an Integrative Resource for Pig Models 
We also present MedSwine, a one-stop resource for engineering the pig genome for human 
biomedical models. MedSwine provide a resource to share aforementioned human disease 
models within the context of the pig genome. It also allows users to navigate, inspect and select 
putative nucleases around target mutation sites. MedSwine is under active development with 
scheduled feature integration. 
P17: Molecular Basis of Atrial Fibrillation in TGF-β Transgenic Goats 
Misha Regouski1, Dustin H. Liechty1, 2, Arnaud Van Wettere1, 2, Heloisa M. Rutigliano1, 2, Irina 
A. Polejaeva1
1Department of Animal, Dairy, and Veterinary Sciences, Logan, UT 2School of Veterinary
Medicine, Utah State University, Logan, UT
Atrial fibrillation (AF) is one of the most prevalent cardiac arrhythmias. Studies have shown 
associations between cardiac fibrosis and incidence of AF, however the underlying mechanisms 
of this relationship is poorly elucidated. Our group has developed the first transgenic goat model 
of cardiac fibrosis. These transgenic goats (with overexpression of human TGF-β1) provide a 
unique platform to study the mechanisms underlying AF. We hypothesize that genes associated 
with the TGF-β signaling pathway, fibronectin, and collagens will be upregulated in the heart 
tissue of transgenic goats, as well as inflammatory cytokines. Atrial and ventricular samples 
were collected from TGF-β1 transgenic goats (n=6) and wild-type controls (n=5).  Transgenic 
animals included in this study expressed the transgene in a cardiac specific manner and exhibited 
increased atrial fibrosis and AF inducibility. Preliminary gene expression analysis was performed 
following standard Fluidigm protocol (Spurgeon et al., 2008). Genes analyzed included 
housekeeping controls, and those associated with TGF-β and fibrosis pathways, inflammatory 
mediators, and apoptosis. Immunohistochemistry was conducted in order to characterize 
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different leukocyte cell populations (CD2+, CD4+, CD8+, CD14+, CD21+, MHC-II+ and 
FoxP3+ cells).  Imaging was done using a high-resolution AxioCam HRC digital camera and 
analyzed using AsioVision software.  We expect to identify an increase in lymphocytes such as 
CD2+, CD4+ and CD8+ T cells and macrophages (CD14+ and MHC-II+) in the myocardium of 
transgenic goats when compared to their wild-type controls. In addition, histological sections 
stained with Masson’s trichrome stain and hematoxylin and eosin were analyzed. Within each 
section 10 randomly selected fields of view were photographed using an Olympus DP 26 digital 
microscope camera and CellSens digital imaging software (Olympus Corporation). Fibrosis 
quantification was determined by measuring percentage area occupied by blue staining 
(Masson’s trichrome stain) of total surface area using Photoshop CS6 (Adobe Systems). 
Cardiomyocyte diameter was assessed by measuring distance of the narrowest plane across the 
cell nucleus for 100 cells from each atrium and ventricle from control and transgenic goats. Data 
generated by these experiments will aid in the identification of the molecular basis of cardiac 
fibrosis and atrial fibrillation in order to facilitate better treatment options for patients with AF. 
P18: Novel Accessible Method to Produce Porcine Chimeric Embryo 
Junchul David Yoon1, Eunsong Lee2 and Sang-Hwan Hyun1* 
1Institute for Stem Cell & Regenerative Medicine (ISCRM), Chungbuk National University, 
Cheongju, 28644, Republic of Korea, 2Laboratory of Theriogenology, College of Veterinary 
Medicine, Kangwon National University, Kangwon, Republic of Korea  
Since the pluripotent stem cells (PSC) was discovered including embryonic stem cells (ESC) and 
induced pluripotent stem cells (iPSC), the PSCs was look forward with the keenest anticipation 
to differentiate functioning organs in regenerative medicine. Recent decade, the studies for 
generation of functional organs have been advanced remarkably with underlying mechanisms for 
production of chimeric animals. However, the procedure of chimeric animal production is 
intricate and it became a major reason of low in vitro production efficiency. The purpose of this 
study is to investigate to establish the novel accessible method to produce porcine chimeric 
embryo. In first, we produced EGFP-marked porcine fibroblast, and then established the EGFP 
labeled porcine ES-like cells via somatic cells nuclear transfer (EGFP-ntESC). The produced 
ntESC were injected into 2-, 4-, and 8 cells stage of cleaved parthenogenesis embryo at day 2 
under microscope with manipulators. We investigated chimeric embryo development, and 
counted total cell number and EGFP-labeled cell number from achieved blastocysts. Data were 
analyzed by ANOVA followed by Duncan using SPSS (Statistical Package for Social Science). 
After day 5 of in vitro chimeric embryo culture (IVC), ES cells injected on the 4- and 8 cells 
stage groups showed significantly higher total blastocyst (49.6% VS 63.9% and 65.6%, 
respectively) and expended blastocyst formation rate (30.2% VS 50.7% and 52.2%, respectively) 
compared with ES cell injected on the 2 cell stage group. Under epifluorescence (460 nm) 
analysis, the 8 cell groups showed significantly higher EGFP-ntESCs number and distribution in 
achieved blastocyst compared with 2 cell group (4.0 and 6.0% VS 1.8 and 3.1%), even though 
we could not find any significant differences on blastocyst total cell numbers (60.6, 73.8, and 
87.6, respectively). In conclusion, ES cell injection on 8 cell stage is applicable to produce 
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porcine chimeric embryo. However, improvement of injected ES distribution in blastocyst 
required for effective production of in vitro chimeric embryo.  
Keywords: porcine, Chimeric embryo, EGFP 
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P19: Reduced Gene Expression and Mitochondrial Function in Porcine Donor-fibroblasts 
Treated with CPI-613 or PS48 Does Not Negatively Impact Subsequent In Vitro Development 
After Somatic Cell Nuclear Transfer 
Bethany R. Mordhorst , Stephanie L. Murphy, Joshua A. Benne, Bethany K. Redel, Lee D. 
Spate,  Kevin D. Wells, Jonathan A. Green, Randall S. Prather.  
Department of Animal Science, University of Missouri, Columbia, MO, United States.  
Early embryos exhibit characteristics of a Warburg Effect (WE)-like metabolism. A hallmark of 
the WE is predominate use of glycolysis for energy production as opposed to the tricarboxylic 
acid (TCA) cycle. In cancer cells increased signaling of the PI3K pathway is correlated with an 
increase in glucose metabolism consistent with the WE. PS48 stimulates the PI3K pathway and 
CPI-613 inhibits pyruvate dehydrogenase. Both compounds should decrease mitochondrial use 
of the TCA cycle and promote the PI3K pathway. The goal was to achieve a WE-like effect in 
donor-cells prior to nuclear transfer (NT) by treating day 35 porcine fetal fibroblasts for 7 days. 
Data were analyzed for main effect of drug via GLM procedure of SAS 9.4 (Cary, NC). JC-10 
was used to determine the mitochondrial membrane potential (Δψm). The percentage of cells 
with high Δψm decreased (P <0.01) with 10µM PS48 (33.4%), CPI 100µM (1.76%), or the 
combination (MIX; 2.81%) compared to control (CON; 46.5 ±3.3%). Expression of mRNA was 
measured by qPCR ΔΔct method. CPI and PS48 decreased PKM M1 variant expression 
compared with control (P< 0.01). Treatments decrease Δψm and PKM M1 abundance, therefore 
metabolism of these potential donor cells may be more WE-like. Fibroblasts treated with CPI, 
PS48, and MIX were used for NT in enucleated oocytes. Cleavage and blastocyst percentages, 
blastocyst cell number, and TUNEL positive cell number were not augmented by donor-cell 
treatment (P >0.14). Drug treatments were tested in the culture of SCNT embryos derived from 
non-drug-treated fibroblasts. Blastocyst development was impacted by drug culture treatment 
(P= 0.05): PS48 and CON had higher percentages (43.3 and 41.2%) compared to CPI and MIX 
(33.6 and 32.7 ±2.9%). TUNEL positive cell number was increased in MIX embryos vs. other 
treatments (P =0.01; MIX =2.1 vs. ≤1.4 ±0.26 in other treatments). Zygotic cleavage rate and cell 
number within blastocysts were not altered with embryonic drug culture (P ≥ 0.07). To date, we 
41
have 3 successful day-35 fetal collections resultant from embryo transfers of PS48 and CPI 
donor-treated clones. Future experiments will further investigate embryonic metabolic 
programming. Funded by Food for the 21st Century and NIH R01HD080636. 
P20: Reprogramming Bovine Fibroblasts to Pluripotency by Fusion to Mouse Embryonic Stem 
Cells 
Maria-Cristina Villafranca, Kaylyn R. Williams, Will H. Eyestone 
Department of Large Animal Clinical Sciences, Virginia-Maryland Regional College of 
Veterinary Medicine, Virginia Tech, Blacksburg, VA 24061, USA  
Embryonic stem cells (ESCs) are pluripotent cell lines derived from preimplantation embryos of 
mice, humans and non-human primates. Induced pluripotent cells (iPSCs) are generated from 
differentiated cells by ectopic expression of transcription factors found in ESCs, and are 
morphologically and functionally equivalent to ESCs. The bovine is an important agricultural 
species for which neither ESCs nor iPSCs exist. Traditional transcription-factor based 
reprogramming, even in the presence of reprogramming enhancers, is insufficient to reprogram 
bovine somatic cells to pluripotency. Mouse and human somatic nuclei can be reprogrammed to 
pluripotency when fused to mouse ESCs (mESCs), suggesting that mESC cytoplasm contains 
reprogramming factors. We hypothesize that mESCs will reprogram bovine somatic cells upon 
fusion and plan to use this model to identify additional/alternative reprogramming factors. We 
developed a cell fusion method using polyethylene glycol and dimethyl sulfoxide (DMSO). 
Additionally, we designed a method to detect and select heterotypic (i.e. mESC/somatic cell; 
heterokaryons) from homotypic fusions (i.e. same cell type fusion products; homokaryons). 
Bovine fibroblasts (BFs) were transduced with a polycistronic lentiviral vector harboring a CMV 
promoter-driven cyan fluorescent protein (CFP) and an Oct4 promoter-driven GFP reporter, as 
well as a puromycin selectable marker. We transduced mESCs with a lentiviral vector harboring 
a CMV promoter-driven monomeric red fluorescent protein (mRFP) reporter. With these tools in 
place, selected BFs and mESCs were fused and monitored for reprogramming by upregulation of 
Oct4-driven GFP expression. We observed expression of Oct4-driven GFP in cells expressing 
both CMV and mRFP. We plan to screen heterokaryons for differentially expressed genes using 
RNA-seq. To avoid lentiviral integrations, we designed an alternative method to label BFs and 
mESCs using fluorescently labeled antibodies. Upon fusion, heterokaryons were labeled with 
anti-bovine CD44 and anti-mouse SSEA-1 antibodies. Heterokaryons positive for both markers 
were manually selected using a micromanipulator. We are currently performing the necessary 
steps for RNA-seq using RNA from <20 heterokaryons. Future research will involve testing 
candidate reprogramming genes for reprogramming activity by forced expression in BFs. We 
plan to further characterize the cells obtained with our new set of candidate factors by 
establishing comparisons with cells reprogrammed with currently known reprogramming factors. 
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P21: Targeted Gene Knock-in by CRISPR/Cas Ribonucleoproteins in Porcine Zygotes 
Ki-Eun Park1,2,3, Anne Powell2, Shelley E.S. Sandmaier1,2, Chan-Mi Kim1,2, Alan Mileham4, 
David M. Donovan2, and Bhanu P. Telugu1,2,3 
1 University of Maryland, Animal and Avian Sciences, College Park, MD, USA; 2 USDA-ARS, 
Animal Bioscience and Biotechnology Laboratory, Beltsville, MD, USA; 3 Livestock Genomix, 
Reisterstown, USA; 4 Genus plc, DeForest, WI, USA  
The domestic pig is an important “dual purpose” animal model for agricultural and biomedical 
applications. There is an emerging consensus in the biomedical community that there is a 
requirement for large animal models such as pigs that can either serve as an alternative, or 
complement investigations from the mouse. However, the use of pig has not proven popular to 
date due in part to technical difficulties and time required in generating desired genetic 
modifications. In this regard, the ability to directly modify the genome in the zygote and generate 
edited animals is highly desirable. This report demonstrates for the first time, the generation of 
gene knock-in animals by direct injection of Cas9 ribonucleoprotein complex and short stretches 
of DNA sequences into porcine zygotes. The Cas9 protein from Streptococcus pyogenes was 
precomplexed with a single guide RNA targeting downstream of the ubiquitously expressed 
COL1A gene, and co-injected with a single-stranded repair template into porcine zygotes. Using 
this approach, pigs that carry pseudo attP sites within the COL1A locus to enable phiC31 
integrase mediated introduction of transgenes have been generated. This new route for genome 
engineering in pigs via zygote injection should greatly enhance applications in both agriculture 
and biomedicine. 
P22: TCET: A Novel Non-surgical Embryo Transfer Device 
Ruonan Liu1, Yanping Miao1, Xinchong Duan1, Mo Guan2, Xiangyun Li1 
1 College of Animal Science and Technology, Agricultural University of Hebei, Baoding, 
Hebei 071000, China. 2 Medical Research Council, Mary Lyon Centre, Harwell Campus, 
Oxfordshire, OX11 0RD, UK 
Although non-surgical transfer of embryos in mice has many advantages over a surgical method, 
the variable success of non-surgical transfer has hampered its acceptance and use. In our studies, 
we discovered that the uterine injury and embryo loss during the procedure are the main causes 
of the variable success for non-surgical transfer. We found that the material and shape of the 
transfer catheter, the implantation-related factors, the volume of transfer medium and the 
techniques of transfer significantly affected embryo implantation. Therefore, we developed a 
novel non-surgical device - TCET (Transcervical Embryo Transfer, Elim Springs Biotech Ltd, 
UK). The device comprises of an arched, thin, soft tip catheter with blunt ends, which will avoid 
or minimize the risk of scratching the endometrium or puncturing the uterine horn during the 
procedure, and the right length of the catheter tip can improve the delivery of the embryos in the 
best position in the uterus for successful implantation. We also refined the transfer techniques 
and the component and volume of transfer medium, which significantly reduces the uterine 
injury and embryo loss and improves the embryo implantation. In these experiments reported 
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here, 62 blastocysts from natural cycle CD1 mice were non-surgically transferred into the uteri 
of 8 CD1 recipient females (2.5d). As the control, 116 embryos were surgically transferred into 
the uteri of 15 CD1 recipient females (2.5d). The results showed that 100% recipient females 
(8/8) got pregnant and gave birth to 51 live pups (82.2%) from TCET transfer. The results from 
the control group were: 93.3% pregnancy rate (15/14) and 70.6% birth rate (82/116). Compared 
with surgical embryo transfer, the procedure of TCET transfer is much simpler, quicker, easier, 
markedly less traumatic and less stressful to the recipient females. In Summary, we established a 
novel and efficient non-surgical embryo transfer using TCET here, which could be an alternative 
to surgical embryo transfer. In addition, this non-surgical embryo transfer technique in mice 
establishes an animal model for the study of rats, cattle, other large animals and human embryo 
transfer techniques. 
P23: The International Society for Transgenic Technologies – Large Animal/Non-Rodent  
Initiative 
Jan Parker-Thornburg1, Bruce Whitelaw2, Martina Crispo3  
1 ISTT, Inc. President, Department of Genetics, MD Anderson Cancer Center, Houston 
TX USA; 2 The Roslin Institute, University of Edinburgh, Midlothian UK; 3 ISTT, Inc. Board 
Member, Transgenic and Experiment Animal Unit, Institut Pasteur, Montevideo, UR  
The International Society for Transgenic Technologies, Inc. (ISTT, Inc.) was founded in January 
2006 in Spain, and was reincorporated in the USA in May, 2013. The Society seeks to foster 
communication and sharing of technology, to enhance scientific research, to advance the field of 
animal transgenesis, particularly as it applies to useful experimental models in biology, medicine 
and biotechnology, and to represent the interest of scientists, technicians, and graduate students 
working in the field of transgenic technologies. The ISTT sponsors a series of periodic 
international meetings known as the Transgenic Technology (TT) Meetings.  At TT2016, held in 
Prague CZ (March 2016), the ISTT instituted a Large Animal/non-Rodent initiative, to be 
headed by Bruce Whitelaw (Roslin Institute) and Martina Crispo (Institute Pasteur, Uruguay, 
ISTT Board member).  The ISTT Board encourages all investigators working in non-rodent 
models to join and contribute to this effort. 
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P24: To Make an Alzheimer’s Disease (AD) Sheep Model Using CRISPR Genome Editing 
Jun Liu1, Jen M. Kelly2, Clive J. McLaughlan3, C. Simon Bawden3, Susanne J. Reid4, Russell G. 
Snell4, Paul J. Verma1,2 
1 Stem Cell and Genetic Engineering Group, Department of Materials Engineering, Monash 
University, Clayton, VIC, Australia; 2 Reproductive Biology, Turretfield Research Centre, South 
Australian Research and Development Institute, Rosedale, SA, Australia; 3 Molecular Biology 
Laboratory, South Australian Research and Development Institute, Roseworthy, SA, Australia; 4 
Centre for Brain Research, School of Biological Sciences, University of Auckland, Auckland, 
New Zealand 
Objective: Presenilin 1, encoded by the PSEN1 gene, is one of four core proteins in the gamma-
secretase complex, which mediates regulated proteolysis of several proteins in the cell, including 
the amyloid precursor protein (APP). Gamma-secretase activity generates specific beta-amyloid 
42) accumulates to form the intraneuronal plaques associated with AD. A simple glutamic acid-
to-alanine mutation at codon 280 (E280A) in PSEN1 alters the activity of gamma-secretase and
results in increased levels of the toxic 42 peptide. To attempt creation of AD sheep, the project
aims to replace the equivalent glutamic acid codon in the sheep PSEN1 protein (E277) with an
alanine codon.
Methods: A pair of 20bp gRNA was designed using online CRISPR design tools. The gRNAs
were annealed and sub-cloned into pSpCas9(BB) and lentiCRISPRv2 backbone vectors using
Zhang’s lab protocols. Two HDR oligos of 202bp and 194pb, respectively, were designed and
synthesized by IDT.
Results:
Functionality of the CRISPR in HEK293T cells: Reporter vectors were constructed using
GeneArt genomic cleavage selection kit. Using lipofactamine 3000 transfection reagents, the
reporter and pSpCas9(BB)-sgRNA vectors were transfected into HEK293T cells. 20 h post
transfection, positive OFP cells were detected under a fluorescence microscope. FACS analysis
showed that 25.6% of the cells were OFP positive.
Functionality of the CRISPR in sheep iPS cells: lentiCRISPRv2-sgRNA#2 was co-transfected
with packaging plasmids pMD2.D and psPAX2 into HEK293T cells to produce lentiviral
particles, which were then transduced into sheep iPS cells using Fugene 6 reagent according to
manufacturer’s instructions. 48 h later, the cells were cultured in medium supplemented with 100
ng/ml puromycin. Genomic DNA was extracted from the surviving colonies. T7EI assay showed
two additional digested products as well as full-length PCR products. Subsequent sequencing
analyses showed that random-sized Indel mutations were created at the desired locus in the iPS
cell colonies.
Generation of targeted sheep mutants by embryo injection of CRISPR mRNA: A mixture of
Cas9 mRNA, sgRNA, and HDR single-strand oligo were injected into the sheep one-cell stage
embryos. The injected embryos were cultured in vitro for blastocyst formation. Genomic DNA
was extracted from the blastocysts and subjected to genotyping. Out of 100 sequenced
blastocysts, 2 embryos showed the HDR mutation in the genome.
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Our transgenic goats are the first of their kind, and may help doctors 
understand and treat the most common heart arrhythmia in humans. 
Learn more about them in Session 3 of the Large Animal Genetic 
Engineering Summit and in the August 2016 issue of the Journal of 
Cardiovascular Electrophysiology.
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